Schizophrenia Research logo Elsevier logo

Publisher: Elsevier

Related content
Volume 24, Number 1, March 1997

< previous issue | all issues | next issue >

Ten years: international congress on schizophrenia research
pp. 3-3(1)
Authors: Nusbaum S.; Schulz C.; Tamminga C.

Schizophrenia and hierarchical diagnosis: a clinical study
pp. 5-5(1)
Authors: Bermanzohn P.C.; Porto L.; Siris S.G.

Periodic catatonia: a case report and literature review
pp. 5-5(1)
Authors: Berry S.A.; Rapport D.J.; Kujawa M.J.

Development of a screening interview and brief diagnostic interview for psychotic disorders
pp. 5-5(1)
Authors: Castle D.J.; Jablensky A.V.; Waterreus A.; McGrath J.; Cardy S.; Herrman H.; Gureje O.

The relationship of schizophrenia and bipolar illness
pp. 6-6(1)
Authors: Lohr J.B.; Caligiuri M.P.

Factors which trigger 'schizophrenia'
pp. 6-7(2)
Authors: Riederer P.; Kornhuber J.

General review on course and prognosis in schizophrenia
pp. 7-7(1)
Authors: Rodado M.J.; Rodado J.; Manzanera F.; Toledo F.; Hernandez J.

Personality and family relationships in schizophrenia in the context of the neurodevelopmental hypothesis
pp. 8-8(1)
Authors: Willinger U.; Heiden A.M.; Meszaros K.; Kasper S.; Aschauer H.N.

Proposals for correlative, concurrent studies in the schizophrenias
pp. 8-8(1)
Authors: Young C.W.; Young L.R.

An investigation of instruments used to assess negative symptoms in patients with schizophrenia
pp. 11-11(1)
Authors: Bow-Thomas C.C.; Eckert S.L.; Miller A.L.; Diamond P.M.; Velligan D.I.; Funderburg L.G.; True J.E.

Sexuality and schizophrenia: behavioral patterns and clinical correlates
pp. 11-11(1)
Authors: Buckley P.F.; Hyde J.; Winterich D.; Friedman L.; Donenwirth K.

Conversational repair in childhood onset schizophrenia
pp. 12-12(1)
Authors: Caplan R.; Guthrie D.; Komo S.

Are psychopathologic domains independent diseases?
pp. 12-12(1)
Author: Carpenter W.T.

Development of the psychosis observation rating scales
pp. 12-12(1)
Authors: Catts S.V.; Andrews S.; Bird K.; Ward P.B.; Liebert B.J.; Spinks N.; McConaghy N.

Correlates and course of negative symptoms in schizophrenic patients
pp. 12-13(2)
Authors: Cohen R.; Watzl H.; Hubmann W.; Mohr F.; Schlenker R.; Werther P.

Quality of life in outpatients with schizophrenia
pp. 13-13(1)
Authors: Dickerson F.; Boronow J.; Ringel N.; Parente F.

Enduring negative or deficit symptoms in first-episode psychosis: comparison of 3 methods using follow-up data
pp. 14-14(1)
Authors: Edwards J.; McGorry P.D.; Waddell F.; Harrigan S.

Aggression among patients with treatment refractory psychoses
pp. 14-14(1)
Authors: Ehmann T.S.; Ross D.; Au T.; Smith G.N.; Flynn S.W.; Altman S.; Honer W.G.

Cigarette smoking: the first episode experience
pp. 14-14(1)
Authors: Elkins K.; Curry C.M.; Harrigan S.M.; McGorry P.D.

Delusions and autism in schizophrenia and immunological alterations
pp. 14-15(2)
Authors: Fabisch H.; Fabisch K.; Langs G.; Wieselmann G.; Tilz G.P.; Zapotoczky H.G.

Obsessive-compulsive symptoms in schizophrenia
pp. 15-15(1)
Authors: Fabisch K.; Fabisch H.; Langs G.; Wieselmann G.; Zapotoczky H.G.

Suicide risk factors in schizophrenia
pp. 15-15(1)
Authors: Fenton W.S.; McGlashan T.H.; Blyler C.R.

PANSS symptom factors in schizophrenia
pp. 15-15(1)
Authors: Fredrikson D.H.; Steiger J.M.; MacEwan G.W.; Altman S.; Kopala L.C.; Flynn S.W.; Liddle P.F.; Honer W.G.

Pubertal timing and syndromes of schizotypy: a replication
pp. 16-16(1)
Authors: Gruzelier J.; Kaiser J.

Suicidal behavior in schizophrenia: an examination of attempters and nonattempters
pp. 16-17(2)
Authors: Harkavy-Friedman J.M.; Restifo K.; Malaspina D.; Kaufmann C.A.; Amador X.; Yale S.; Gorman J.M.

The putative phenomenological correlates of sensory gating: factor analyses and a self-report rating scale
pp. 17-17(1)
Authors: Hetrick W.P.; Smith D.A.; Spruiell E.; Sandman C.A.; Bunney W.E.

Patterns of symptom change: a longitudinal analysis
pp. 17-18(2)
Authors: Hull J.W.; Smith T.E.; Anthony D.T.; Goodman M.S.; Kentros M.K.; Sepe O.; Yanulis M.A.; Li C.

Symptom dimensions in schizophrenia: a comparison of white and African-Caribbean patients
pp. 18-18(1)
Authors: Hutchinson G.; Takei N.; Fahy T.A.; Gilvarry C.; Murray R.M.

Symptom and disease specificity of brain behavior functions in bipolar disorder and schizophrenia
pp. 18-18(1)
Authors: Kohler C.; Gur R.C.; Mozley L.H.; Gur R.E.

Sex differences in self-reported schizotypal symptoms in relatives of schizophrenic probands
pp. 18-19(2)
Authors: Kremen W.S.; Faraone S.V.; Seidman L.J.; Toomey R.; Lyons M.J.; Goldstein J.M.; Tsuang M.T.

Recruitment of schizophrenia spectrum personality subjects from the community
pp. 19-19(1)
Authors: Kunkel R.; Adami H.; Ross D.; Thaker G.K.

Social problem solving and social withdrawal in adolescents at-risk for schizophrenia
pp. 19-19(1)
Authors: Logan M.C.; Schiffman J.; Walder D.; Walker E.F.

Psychopathology in first-episode familial schizophrenia
pp. 19-19(1)
Authors: Nilsson A.; Ahrens B.

A profile of obsessive compulsive symptoms in schizophrenia
pp. 20-20(1)
Authors: Porto L.; Bermanzohn P.; Siris S.; Pollack S.; Morrissey R.

Core negative and positive symptoms in schizophrenia
pp. 20-20(1)
Authors: Quinlan D.M.; McGlashan T.H.; Schuldberg D.; Glazer W.

Emotional response and symptoms of schizophrenia
pp. 20-21(2)
Authors: Quirk S.W.; Strauss M.E.; Sloan D.M.

Predictors of assaultive long-stay schizophrenic patients: national study
pp. 21-21(1)
Authors: Rabinowitz J.; Mark M.; Popper M.

Prediction of outcome following a first episode of schizophrenia. A preliminary study
pp. 21-21(1)
Authors: Rodado M.J.; Manzanera F.; Lopez J.C.; Sanchez de las Matas M.; Aguilar E.; Hernandez J.

Agreement between SPQ and MMPI-2 as measures of schizotypy
pp. 21-21(1)
Authors: Sarkin A.J.; Dionisio D.P.; Hillix W.A.; Granholm E.L.

Schizophrenia and substance abuse: characteristics associated with the high rate of comorbidity
pp. 22-22(1)
Authors: Scheller-Gilkey G.; Thomas S.; Chadwick N.; Woolwine B.; Miller A.

Negative symptom severity and general cognitive impairment increase with duration of initially untreated psychosis
pp. 22-22(1)
Authors: Scully P.J.; Coakley G.; Kinsella A.; Waddington J.L.

Laterality in parkinson's disease and susceptibility to psychosis
pp. 22-22(1)
Authors: Shergill S.S.; Walker Z.; Katona C.L.E.

Computerized self-assessment of psychosis severity [COSAPS] in schizophrenia. A preliminary report on the COSAPS-questionnaire
pp. 23-23(1)
Authors: Stern R.G.; Fudge R.; Sisson C.; Alan E.; Crichton J.; Schmeidler J.; Losonczy M.

Rater gender and symptom ratings of patients with schizophrenia
pp. 23-23(1)
Authors: Swanson C.L.; Turetsky B.I.; Bilker W.; Gur R.C.; Gur R.E.

Negative, positive, and disorganized symptom dimensions in schizophrenia, major depression, and bipolar disorder
pp. 24-24(1)
Authors: Toomey R.; Faraone S.V.; Simpson J.C.; Tsuang M.T.

Sequential models of schizophrenia courses
pp. 24-24(1)
Authors: Tschacher W.; Scheier C.

Olfactory discrimination and acuity in relation to positive and negative symptoms
pp. 24-24(1)
Authors: Vernon L.; Bartel B.; Brown K.; Steele V.; Cho J.; Simon M.; Jaskiw G.E.; Strauss M.E.

Three dimensions of selfreport schizotypy
pp. 24-25(2)
Authors: Vollema M.G.; Hoijtink H.

Symptoms cluster analysis on and off neuroleptic medication
pp. 25-25(1)
Authors: Warfel D.T.; Lahti A.C.; Corey T.; Weiler M.A.; Medoff D.; Tamminga C.A.

The prevalence and predictive validity of early depressive symptoms in the course of schizophrenia
pp. 25-25(1)
Authors: Wassink T.H.; Rose S.; Flaum M.; Andreasen N.C.

Symptom severity in chronic schizophrenia: effect of age and cognitive impairment
pp. 25-26(2)
Authors: White L.; Parrella M.; Harvey P.D.; Powchick P.; Davidson M.; Opler L.; Lindenmayer J.

Adhesive and positional specification in the developing forebrain
pp. 27-27(1)
Authors: Gotz M.; Cremisi F.; Price J.

A neural model of psychosis in temporal lobe epilepsy
pp. 27-28(2)
Authors: Diforio D.; Walker E.F.

The effect of chronic haloperidol treatment on dendritic spines in the rat striatum
pp. 28-28(1)
Authors: Kelley J.J.; Gao X.M.; Tamminga C.A.; Roberts R.C.

An animal model of relevance to the deficit syndrome
pp. 28-28(1)
Author: Kirkpatrick B.

Limbic-cortical neuropathology in rats: a developmental study
pp. 28-28(1)
Authors: Montgomery E.-M.E.; Bardgett M.E.; Csernansky J.G.

Schizophrenia-like limbic-cortical neuropathology in rats: fos response to antipsychotics
pp. 29-29(1)
Authors: Roe D.L.; Bardgett M.E.; Csernansky C.A.; Csernansky J.G.

Localization of D4-like dopamine receptors on corticostriatal projections and intrinsic striatal neurons
pp. 29-30(2)
Authors: Tarazi F.I.; Yeghiayan S.K.; Campbell A.; Baldessarini R.J.

Regional measurement of pH in postmortem brain tissue
pp. 31-31(1)
Authors: Bigelow L.B.; Cervenak J.; Herman M.M.; Kleinman J.E.; Torrey E.F.

Correlation of schizophrenia and bipolar disorder with cytokine and nitric oxide synthase levels from post-mortem brain tissues
pp. 31-31(1)
Authors: Bobo L.; Novak N.; Johnston N.; Leister F.; Torrey E.F.; Yolken R.

Biochemical heterogeneity in schizophrenia due to gender: a multivariate study of post-mortem brain biochemistry
pp. 31-32(2)
Authors: Carlsson A.; Waters N.; Waters S.H.; Carlsson M.; Gottfries C.-G.; Martin P.; Hansson L.O.

Lateralised alterations in hippocampal MAP2 in schizophrenia
pp. 32-32(1)
Authors: Cotter D.R.; Doshi B.; Kerwin R.W.; Everall I.P.

A possible muscarinic involvement in schizophrenia: reduced M1 receptor measurement in human hippocampus
pp. 32-33(2)
Authors: Crook J.M.; Tomaskovic E.M.; Dean B.; Copolov D.

Second messengers in schizophrenia: changes in protein kinase C and adenylate cyclase
pp. 33-33(1)
Authors: Dean B.; Opeskin K.; Pavey G.; Hill C.; Keks N.

Absence of neuropathological and neurochemical sequela of cognitive deficits in elderly schizophrenics
pp. 33-33(1)
Authors: Haroutunian V.; Powchik P.; Gabriel S.; Purohit D.P.; Perl D.P.; Davis K.L.

Cortex and serotonin in schizophrenia: effects of antipsychotic treatment?
pp. 33-34(2)
Authors: Joyce J.N.; Gurevich E.V.

Reduced levels of synaptic proteins in the prefrontal cortex in schizophrenia
pp. 34-34(1)
Authors: Karson C.N.; Griffin W.S.; Mrak R.E.; Sturner W.Q.; Shillcutt S.; Guggenheim F.G.

Diagnostic instrument for brain studies (DIBS)
pp. 34-34(1)
Authors: Keks N.A.; Hill C.; Roberts S.; Dean B.; Opeskin K.; MacKinnon A.; Copolov D.

[3H]-NGD-94-1 binding in human postmortem brain of normals and schizophrenics off-, or on-antipsychotic drugs at death
pp. 35-35(1)
Authors: Lahti R.A.; Roberts R.C.; Cochrane E.V.; Primus R.J.; Gallager D.W.; Tamminga C.A.

Postmortem glutamate receptor binding in the prefrontal cortex of schizophrenics and controls
pp. 35-35(1)
Authors: Noga J.T.; Hyde T.M.; Bachus S.E.; Herman M.M.; Weinberger D.R.; Kleinman J.E.

Parvalbumin-IR neurons in the frontal cortex in schizophrenia
pp. 35-36(2)
Authors: Reynolds G.P.; Beasley C.L.

Post-mortem determination of kynurenine and kynurenic acid levels in the brains of schizophrenic patients
pp. 36-36(1)
Authors: Schwarcz R.; Wu H.-Q.; Rassoulpour A.; Tamminga C.A.; Medoff D.R.; Roberts R.C.

Phosphoinositide signaling activity in postmortem brain from subjects with schizophrenia or alcohol dependence
pp. 36-36(1)
Authors: Stockmeier C.A.; Song L.; Dilley G.E.; Meltzer H.Y.; Overholser J.C.; Jope R.S.

An immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia: absence of significant gliosis
pp. 37-37(1)
Authors: Damadzic R.; Goldenson D.A.; Saunders R.C.; Krimer L.S.; Bigelow L.B.; Herman M.M.; Kleinman J.E.

The frontal lobe in schizophrenics and control subjects: a volumetric post-mortem-study
pp. 37-38(2)
Authors: Falkai P.; Bogerts B.; Schneider T.; Pfeiffer U.; Honer W.G.; Kawasaki Y.

Serotonergic neurons in the dorsal raphe nuclei in schizophrenia
pp. 38-38(1)
Authors: Garey L.J.; Kavia R.B.C.; von Bussmann K.A.; Gentleman S.M.

A quantitative study of parvalbumin-immunoreactive interneurons in the cingulate gyrus of schizophrenic patients
pp. 38-38(1)
Authors: Leclercq P.D.; McKenzie J.E.; Royston M.C.; Gentleman S.M.; Mortimer A.M.; von Bussmann K.A.; Hornstein C.; Bauer M.; Hirsch S.R.; Garey L.J.

Schizophrenia and subclasses of local circuit neurons in the prefrontal cortex
pp. 38-39(2)
Authors: Lewis D.A.; Woo T.-U.; Miller J.L.; Soloway A.S.

An assessment of purkinje cell placement in the superior cerebellar vermis in mental disease
pp. 40-40(1)
Authors: Paltan-Ortiz J.D.; Helmkamp C.E.; Bigelow L.B.; Torrey E.F.; Kleinman J.E.; Herman M.M.

A neuroanatomical study of glial cells in schizophrenia
pp. 40-41(2)
Authors: Radewicz K.; Garey L.J.; Hirsch S.R.; Mortimer A.M.; Hornstein C.; Bauer M.; Reynolds R.

Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia
pp. 41-41(1)
Authors: Rajkowska G.; Selemon L.D.; Goldman-Rakic P.S.

The immunocytochemical localization of tyrosine hydroxylase in the human substantia nigra: an ultrastructural study
pp. 41-41(1)
Authors: Roberts R.C.; McKim R.; Kung L.; Crosby K.; Chute D.J.

Morphometric study of synaptic size in autopsied prefrontal cortex, caudate nucleus and substantia nigra of schizophrenics
pp. 41-42(2)
Authors: Uranova N.A.; Orlovskaya D.D.; Kolomeets N.S.; Vikchreva O.V.; Zimina I.S.; Denisov D.V.

Hippocampal presynaptic proteins in schizophrenia
pp. 42-42(1)
Authors: Young C.; Beach T.G.; Arima K.; Falkai P.; Honer W.G.

Schizophrenics and their adopted-away offspring the finnish adoptive family study of schizophrenia
pp. 43-43(1)
Authors: Tienari J.P.; Wynne C.L.; Laksy K.; Kurki-Suonio K.; Sorri A.; Lahti I.; Moring O.J.; Wahlberg K.-E.H.

The genetic epidemiology of schizophrenia in a finnish twin cohort
pp. 43-44(2)
Authors: Cannon T.D.; Kaprio J.; Lonnqvist J.; Huttunen M.; Koskenvuo M.

Assortative mating and lifetime DSM-III-R outcome in offspring of schizophrenic and normal parents
pp. 44-44(1)
Authors: Finkelstein R.J.J.; Cannon D.T.; Mednick A.S.; Parnas J.; Schulsinger F.

Evaluation of the effectiveness of early predictors of schizophrenia spectrum disorders in the New York high-risk project
pp. 44-44(1)
Authors: Erlenmeyer-Kimling L.; Rock D.; Janal M.; Amminger G.P.; Squires-Wheeler E.; Ott S.; Rende R.; Cornblatt B.; Roberts S.; Pape S.

The New York high-risk project: social and general intelligence in subjects at risk for and prior to onset of schizophrenia
pp. 44-44(1)
Authors: Ott S.L.; Spinelli S.; Rock D.; Roberts S.; Amminger P.G.; Erlenmeyer-Kimling L.

Cognitive/neuropsychological abnormalities in the parents of children with a schizophrenic disorder
pp. 45-45(1)
Authors: Asarnow R.F.; Nuechterlein K.H.; Torquato R.; Subotnik K.; Fogelson D.

Object alteration deficits in first-degree relatives of schizophrenic patients
pp. 45-45(1)
Authors: Faraone S.V.; Seidman L.J.; Oscar-Berman M.; Kremen W.S.; Toomey R.; Tsuang M.T.

What clinical characteristics distinguish relatives of schizophrenics from normal controls?
pp. 45-45(1)
Authors: Levy D.L.; Bloom R.; Matthysse S.; Teraspulsky L.; Mendell N.R.; Holzman P.S.

MMPI profiles of first-degree relatives of recent-onset schizophrenia probands
pp. 46-46(1)
Authors: Nuechterlein K.H.; Subotnik K.L.; Asarnow R.F.; Gottesman I.I.; Fogelson D.L.; Payne D.L.; Torquato R.D.

Increase of neurological abnormalities in females with schizotypal personality disorder from families multiply affected with schizophrenia
pp. 46-46(1)
Authors: Sigmundsson T.; Takei N.; Griffiths T.D.; Birkett P.B.; Sharma T.; Frangou S.; Murray R.M.

MMPI differences among first-degree relatives of probands with childhood-onset schizophrenia, attention deficit disorder, and normal control children
pp. 46-46(1)
Authors: Subotnik K.L.; Asarnow R.F.; Nuechterlein K.H.; Payne D.L.; Fogelson D.L.; Gottesman I.I.

The factor structure of schizophrenia spectrum signs and symptoms in first-degree relatives of schizophrenic patients from the UCLA family members study
pp. 47-47(1)
Authors: Fogelson D.L.; Nuechterlein K.H.; Asarnow R.F.; Payne D.L.; Subotnik K.L.; Giannini C.

Morbid risk of affective psychoses in the relatives of white and African-Caribbean schizophrenic probands
pp. 47-47(1)
Authors: Hutchinson G.; Takei N.; Fahy T.A.; Gilvarry C.; Murray R.M.

Affective illness in the mother as a risk factor for obstetric complications
pp. 47-48(2)
Authors: Marcelis M.; van Os J.; Sham P.; Jones P.; Gilvarry K.; Murray R.

Psychopathological dimensions and familial morbid risk of psychosis
pp. 48-48(1)
Authors: Marcelis M.; van Os J.; Sham P.; Jones P.; Gilvarry K.; Murray R.

How do co-familial traits segregate?
pp. 48-48(1)
Authors: Matthysse S.; Levy D.L.; Deutsch C.; Bloom R.; Coleman M.J.; Yurgelun-Todd D.; Holzman P.S.

Spatial working memory impairment in schizophrenics and their relatives
pp. 48-49(2)
Authors: Snitz B.E.; Feil K.J.; Zald D.H.; Iacono W.G.

Verbal memory deficits in schizophrenic patients and their siblings
pp. 49-49(1)
Authors: White P.T.; Cannon T.D.; Gur R.C.

Abnormal subjective experiences and neuropsychological deficits in first-degree relatives of schizophrenics
pp. 49-49(1)
Authors: Wieneke A.; Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders
pp. 49-50(2)
Authors: Silverman J.M.; Li G.; Smith C.J.; Song L.G.; Mohs R.C.; Siever L.J.; Davis K.L.

Sibling concordance for schizophrenia spectrum traits
pp. 50-50(1)
Authors: Squires-Wheeler E.; Skodol A.; Erlenmeyer-Kimling L.

A susceptibility locus for schizophrenia on chromosome 6 using positive symptom scores as quantitative traits
pp. 50-50(1)
Authors: Bassett A.S.; Honer W.G.; Chow E.; McAlduff J.; Hodgkinson K.A.; Kirkham S.J.; Brzustowicz L.M.

Evidence for a resistance locus for schizophrenia close to the HLA DQB1 and DRB1 gene loci on chromosome 6p21.3
pp. 50-51(2)
Authors: Wright P.; Donaldson P.T.; Underhill J.A.; Choudhuri K.; Doherty D.G.; Murray R.M.

Evidence from a transmission/disequilibrium study that alleles of the DRB1*04 gene on chromosome 6p21.3 may protect against schizophrenia
pp. 51-51(1)
Authors: Wright P.; Dawson E.; Donaldson P.T.; Underhill J.A.; Sham P.C.; Gill M.; Nanko S.; Owen M.J.; McGuffin P.; Murray R.M.

Association between schizophrenia and markers on chromosome 6p21
pp. 51-51(1)
Authors: Nimgaonkar V.L.; Rudert W.A.; Zhang F.; Gentry K.; Barron Y.; Snider A.; Zhang X.R.; Ganguli R.; Trucco M.

Major psychoses and a potential vulnerability locus on 6p24-p22 in the eastern Quebec population
pp. 52-52(1)
Authors: le groupe IREP and Chantal Merette; Maziade M.; Roy M.-A.; Bissonnette L.; Martinez M.; Cliche D.; Fournier J.-P.; Montgrain N.

Linkage of a chromosome 15 locus to a neurophysiological deficit in schizophrenia
pp. 52-52(1)
Authors: Leonard S.; Byerley W.; Myles-Worsley M.; Olincy A.; Waldo M.; Adler L.; Coon H.; Freedman R.

Linkage studies in schizophrenia and affective disorders in European populations
pp. 52-52(1)
Authors: Maier W.; Albus M.; Lerer B.; Schwab S.; Noethen N.; Risch N.; Fimmers R.; Propping P.; Wildenauer D.B.

A linkage disequilibrium study of chromosome 4p16 and schizophrenia
pp. 53-53(1)
Authors: Shaikh S.; Collier D.; Chioza B.; Tao L.; Xiche L.; Kerwin R.

Velo-Cardio-Facial Syndrome: a true genetic subtype of schizophrenia?
pp. 53-53(1)
Authors: Hodgkinson K.A.; Chow E.; Correia S.; Scutt L.; McAlduff J.; Beatty B.; Squire J.; Weksberg R.; Bassett A.S.

Velocardiofacial syndrome (VCFS) in schizophrenia: cognitive features
pp. 53-53(1)
Authors: Bury A.S.; Chow E.W.C.; Weksberg R.; Correia S.; Scutt L.; Bassett A.S.

Craniofacial dysmorphology in schizophrenia
pp. 53-54(2)
Authors: Deutsch C.K.; Price S.F.; Wussler J.; D'Agostino R.

Upward shift in the distribution of dysmorphic features in schizophrenia
pp. 54-54(1)
Authors: Lane A.; Larkin C.; Waddington J.L.; O'Callaghan E.

Anticipation and imprinting in schizophrenia: results from a large representative Canadian archival sample
pp. 54-54(1)
Authors: Bassett A.S.; Scutt L.; Correia S.; Bomba M.; Husted J.M.

Anticipation and cohort-effect in schizophrenia
pp. 54-55(2)
Authors: Heiden A.; Mag U.W.; Scharfetter J.; Meszaros K.; Kasper S.; Aschauer H.N.

Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia
pp. 55-55(1)
Authors: Vincent J.B.; Meltzer H.Y.; Lieberman J.A.; Breschel T.; McGinnis M.; Macedo A.; Azevedo M.H.; Pato C.N.; Torrey E.F.; Gottesman I.I.; Petronis A.; Kennedy J.L.

Detection, quantitation and analysis of genomic differences in monozygotic twins
pp. 55-55(1)
Authors: Smith C.L.; Broude N.E.; Lukyanov S.A.; Graber J.H.; Sverdlov E.D.

Analysis of genomic DNA from monozygotic twins discordant for schizophrenia
pp. 55-56(2)
Authors: Yeping S.; Lin J.-J.; Shuojia L.; Leister F.; Yolken R.

Molecular genetic analysis of a translocation breakpoint associated with schizophrenia
pp. 56-56(1)
Authors: Devon R.S.; Millar J.K.; Anderson S.; Christie S.; Maule J.C.; Shibasaki Y.; Evans K.L.; Brown J.; Wilson-Annan J.C.; Lawson D.; Gosden J.R.; Muir W.J.; Blackwood D.H.R.; St. Clair D.M.; Brookes A.J.; Porteous D.J.

Mental correlates of neuromotoric deviation in 6-year-olds at heightened risk for schizophrenia
pp. 56-56(1)
Authors: McNeil T.F.; Cantor-Graae E.; Blennow G.

The NIMH schizophrenia genetics initiative: a new scientific resource
pp. 57-57(1)
Authors: Moldin S.O.; Wynne D.; Shore D.

Genetics, haloperidol-induced catalepsy and haloperidol effects on prepulse inhibition of acoustic startle
pp. 59-59(1)
Authors: Hitzemann R.; McCaughran J.; Kline L.; Fochtman L.; Mahjubi I.

Regulation of glutamate receptor gene expression in the rat brain following antipsychotic drug treatment
pp. 59-60(2)
Authors: Riva M.A.; Tascedda F.; Lovati E.; Racagni G.

Inheritance of a schizophrenia-like deficit in auditory gating fits a one gene model in inbred mouse strains
pp. 60-60(1)
Authors: Stevens K.E.; Collins A.C.; Marks M.J.; Stitzel J.A.; Freedman R.

Molecular approaches towards the evaluation of the retroviral hypothesis for schizophrenia
pp. 60-60(1)
Authors: Deb P.; Klempan T.A.; Singh S.M.; O'Reilly R.L.

Viral and virus-related RNA transcripts are differentially expressed in the brains of individuals with schizophrenia and bipolar disorder
pp. 60-61(2)
Authors: The Stanley Neuropathology Consortium; Yee F.; Johnston N.L.; Leister F.; Li S.; Ross C.A.; Torrey E.F.; Yolken R.H.

Molecular analyses of brains from individuals with schizophrenia-evidence of viral infections
pp. 61-61(1)
Authors: the Stanley Neuropathology Consortium; Yolken R.H.; Yee F.; Johnston N.; Leister F.; Bobo L.; Jafari N.; Brando L.J.; De I.; Torrey E.F.

The effects of treated and untreated nicotine withdrawal on smokers with schizophrenia
pp. 63-63(1)
Authors: Dalack G.W.; Becks L.; Hill E.; Pomerleau O.; Meador-Woodruff J.H.

Cortisol response to a psychosocial stressor in schizophrenia
pp. 63-63(1)
Authors: Gispen-de Wied C.C.; Jansen L.M.C.; van der Linden J.A.; Kahn R.S.

Arachidonic and docosahexaenoic acid levels in blood in schizophrenics who do and do not flush to oral niacin
pp. 64-64(1)
Authors: Horrobin D.F.; Vaddadi K.S.; Glen A.I.M.; Cooper S.; Fahey J.; Rybakowski J.; Shay J.

Anticardiolipin antibodies in schizophrenia
pp. 65-65(1)
Authors: Kolyaskina G.I.; Burbaeva O.A.; Sekirina T.P.

Gonadotropin activity in men and women with schizophrenia
pp. 65-66(2)
Authors: Kulkami J.; de Castella A.; Taffe J.

Menstrual cycle changes in schizophrenia
pp. 66-66(1)
Authors: Kulkami J.; de Castella A.; Thompson K.; Smith D.

Plasma TBARS levels in unmedicated chronic schizophrenic patients
pp. 66-66(1)
Authors: Peet M.; Zhi J.Z.; Selvam K.; Ramchand C.N.

Free radical pathology in schizophrenia: a review
pp. 67-67(1)
Authors: Reddy R.; Yao J.K.

CSF HVA/5HIAA ratio is normally distributed in unmedicated and clozapine treated schizophrenics as compared with normal controls
pp. 67-67(1)
Authors: Risch S.C.; Molloy M.; Batchelor M.; Speer A.; Lewine R.R.J.; DeVane C.L.; George M.

Aminochromes, neuromelanin and schizophrenia
pp. 67-68(2)
Author: Smythies J.

Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
pp. 68-68(1)
Authors: Guochuan T.; van Kammen D.P.; Shao C.; Kelley M.E.; Coyle J.T.

CSF neuronal cell adhesion molecule (N-CAM) in schizophrenia
pp. 68-69(2)
Authors: van Kammen D.P.; Poltorak M.; Kelley M.E.; Yao J.K.; Gurklis J.A.; Peters J.L.; Hemperly J.J.; Freed W.J.

The role of immune measures in psychosis and stress sensitivity in schizophrenia
pp. 69-69(1)
Authors: van Kammen D.P.; McAllister C.G.; Kelley M.E.; Mathe A.A.; Brown W.A.; Yao J.K.; Gurklis J.A.

Cellular effects of serum osmolarity changes in polydipsia-hyponatremia
pp. 69-69(1)
Authors: Verghese C.; Levitan I.; Garber S.; Nair C.; Abraham G.; Josiassen R.

Stress and schizophrenia: new neurochemical findings and models
pp. 69-70(2)
Authors: Walker E.F.; Diforio D.; Logan C.

Skin flushing in response to graded doses of topical niacin: a new test which distinguishes schizophrenics from controls
pp. 70-70(1)
Authors: Ward P.; Sutherland J.; Glen E.; Glen A.I.M.; Horrobin D.F.

Obstetrical complications and stress-responsitivity in adolescents at-risk for schizophrenia
pp. 70-70(1)
Authors: Weinstein D.D.; Lowey R.; Diforio D.; Walker E.F.

Neuroleptic effects on antioxidant defense system enzymes in schizophrenia
pp. 70-71(2)
Authors: Yao J.K.; van Kammen D.P.; Reddy R.D.

Serotonergic modulation of the GABA system in the rat prefrontal cortex
pp. 73-73(1)
Authors: Abi-Saab W.M.; Deutch A.Y.

Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo
pp. 74-74(1)
Authors: Bymaster F.P.; Li X.-M.; Carter P.A.; Wong D.T.; Perry K.W.

Clozapine impairs temporal perception and stimulus control in rats
pp. 75-75(1)
Authors: Compton A.D.; Drew M.R.; Golden K.M.; Wiley J.L.

The antiseizure efficacies of MK-801, phencyclidine, ketamine and memantine are altered selectively by stress
pp. 75-75(1)
Authors: Deutsch S.I.; Mastropaolo J.; Riggs R.L.; Rosse R.B.

Behavioral and biochemical changes in amphetamine sensitized rats: comparison of clozapine, haloperidol, and PNU-101387G
pp. 75-76(2)
Authors: Feldpausch D.L.; Meng Z.-H.; Needham L.M.; Stone M.P.; Svensson K.A.; Merchant K.M.

Induction of FOS protein immunoreactivity in the rat forebrain by the dopamine D3-selective constrained benzindole cis-8-OH-PBZI
pp. 76-76(1)
Authors: Fink-Jensen A.; Ludvigsen T.S.; Larsen P.J.; Scheideler M.; Korsgaard N.

Blockade of phencyclidine- and MK801-induced regional zif268 mRNA expression
pp. 76-76(1)
Authors: Gao X.-M.; Chen L.-W.; Tamminga C.A.

Developmentally specific disruptions of prepulse inhibition: sensitivity to antipsychotics
pp. 76-77(2)
Authors: Geyer M.A.; Bakshi V.; Braff D.L.; Swerdlow N.R.

Ziprasidone: preclinical profile of a new antipsychotic agent
pp. 77-77(1)
Authors: Gunn K.P.; Heym J.; Zorn S.H.

In vivo occupancy of D2 dopamine receptors by D3 receptor-selective drugs
pp. 79-79(1)
Authors: Levant B.; Bancroft G.N.; Selkirk C.M.; Vansell N.

The nature of the action of amphetamine in the disrupted latent inhibition model of schizophrenia
pp. 80-80(1)
Authors: Moran P.M.; Peters S.L.; Young A.M.J.; Gray J.A.; Joseph M.H.

S(+)-N-n-propylnorapomorphine ([+]-NPA): a novel atypical antipsychotic with clozapine-like effects
pp. 82-82(1)
Authors: Tarazi F.I.; Yeghiayan S.K.; Baldessarini R.J.; Neumeyer J.L.

Further evidence for a role of the 5-HT2A receptor in the mediation of antipsychotic activity
pp. 83-83(1)
Authors: Wadenberg M.-L.G.; Hicks P.B.; Young K.A.; Richter J.T.

Modulation of dopamine by norepinephrine in the prefrontal cortex
pp. 84-84(1)
Authors: Yamamoto B.K.; Mieskoski D.

3orrelation between NMDA receptor mRNA in temporal cortex and antemortem cognitive impairment in schizophrenia
pp. 85-85(1)
Authors: de Belleroche J.; Humphries C.; Durnin A.; Mortimer A.; Hirsch S.

Ionotropic glutamate receptor mRNA expression in schizophrenia
pp. 87-88(2)
Authors: Meador-Woodruff J.H.; Healy D.J.; Damask S.P.; Haroutunian V.; Powchik P.; Davidson M.; Davis K.L.; Watson S.J.

Quantitative analysis of dopamine D4 gene expression in control and schizophrenic post mortem tissue
pp. 88-88(1)
Authors: Stefanis N.; Bresnick J.; Kerwin R.; McAllister G.

Altered gene expression in the striatum following chronic neuroleptic therapy
pp. 89-89(1)
Authors: Rushlow W.; Naus C.G.; Flumerfelt B.A.; Rajakumar N.

Pharmacogenetic factors in treatment-resistant schizophrenia: the role of CYP2D6 variants
pp. 89-89(1)
Authors: Aitchison K.J.; Munro J.; Wright P.; Chapman S.; Collier D.A.; Kerwin R.W.

Polymorphisms in the 5-HT2A receptor gene and promoter region associated with clozapine response
pp. 90-90(1)
Authors: Arranz M.J.; Munro J.; Sham P.; Zhao J.; Kirov G.; Sodhi M.; Spurlock G.; Owen M.; Collier D.A.; Kerwin R.

Regulation of the internalization of the 5HT2A receptor in vitro
pp. 90-90(1)
Authors: Berry S.A.; Alsayegh L.; Roth B.L.

No association between a novel polymorphism in the 5-HT4 receptor gene and response to clozapine
pp. 90-90(1)
Authors: Birkett J.T.P.; Collier D.A.; Munro J.; Arranz M.J.; Roberts G.W.; Price J.; Kerwin R.W.

Allelic variation of the 5-HT2C receptor in psychosis
pp. 90-91(2)
Authors: Sodhi M.S.; Kirov G.; Aitchison K.J.; Arranz M.J.; Collier D.A.; Kerwin R.W.

Meta-analysis of association studies between schizophrenia and polymorphisms of the 5-hydroxytryptamine type 2A receptor gene
pp. 91-91(1)
Authors: Spurlock G.; Williams J.; McGuffin P.; Mallet J.; Nothen M.; Gill M.; Aschauer H.; Adolfsson R.; Macciardi F.; Owen M.J.

Lack of association between 5HT2A, 5HT2C, and D4 receptor gene polymorphisms and the deficit syndrome of schizophrenia
pp. 91-91(1)
Authors: Buchanan R.W.; Malhotra A.; Kirkpatrick B.; Goldman D.; Breier A.; Pickar D.

Childhood-early adolescence onset and adult onset schizophrenia: heterogeneity at the dopamine D3 receptor gene
pp. 92-92(1)
Authors: Maziade M.; Roy M.-A.; Martinez M.; Gauthier B.; Tremblay G.; Fournier C.; Bissonnette L.; Simard C.; Rouillard E.; Merette C.

The spatial expression pattern of the D4 gene in the human brain
pp. 92-92(1)
Authors: Mulcrone J.; Kerwin R.

D1 alleles predict clinical response to clozapine and corresponding brain metabolism: a genetic pet scan study
pp. 92-92(1)
Authors: Potkin S.G.; Kennedy J.; Badri F.; Yi J.; Masellis M.; Gulasekaram B.; Costa J.; Keator D.B.; Telford J.; Wu J.C.; Najafi A.

An investigation of the GLUR6 receptor gene (GRIK2) in schizophrenia
pp. 93-93(1)
Authors: Bolonna A.A.; Makoff A.J.; Collier D.A.; Kirov G.; Munro J.; Arranz M.J.; Kerwin R.W.

Is the polymorphic (CA)n repeat at the human cPLA2 locus associated with schizophrenia?
pp. 93-93(1)
Authors: Lee K.H.; Wei J.; Ramchand C.N.; Peet M.

APOE4 allele frequency is not increased in demented schizophrenics: a study of 116 patients with concomitant postmortem examination
pp. 93-93(1)
Authors: Powchik P.; Haroutunian V.; Greenberg D.; Altsteil L.; Purohit D.; Perl D.; Davidson M.

Apolipoprotein E and schizophrenia: association with clinical response to clozapine
pp. 93-94(2)
Authors: Royston M.C.; Bell R.; Collier D.; Kerwin R.W.; Roberts G.W.

Neuropsychological impairment in schizophrenia
pp. 95-95(1)
Authors: Albus M.; Hubmann W.; Sobizack N.; Wahlheim C.; Franz U.; Mohr F.

Substance abuse and neurocognitive function in schizophrenia
pp. 95-96(2)
Authors: Allen D.N.; Gilbertson M.W.; Seaton B.E.; Gurklis J.A.; Barry E.J.; van Kammen D.P.

Utility of WAIS-R short forms in schizophrenia
pp. 96-96(1)
Authors: Allen D.N.; Huegel S.G.; Seaton B.E.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

WAIS-R factor structure in schizophrenia
pp. 96-96(1)
Authors: Allen D.N.; Huegel S.G.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

Awareness deficits in neurological disorders and schizophrenia
pp. 96-97(2)
Authors: Amador X.F.; Barr W.B.; Economou A.; Mallin E.; Marcinko L.; Yale S.A.

Behavior problems in childhood and psychiatric outcomes in adulthood in the subjects of the New York High-Risk Project
pp. 97-97(1)
Authors: Amminger G.P.; Squires-Wheeler E.; Looser-Ott S.; Roberts S.; Pape S.; Rende R.; Rock D.; Erlenmeyer-Kimling L.

The ontogeny of schizophrenia
pp. 97-97(1)
Author: Asarnow R.F.

The 'benefits' of distractibility: mechanisms underlying increased stroop facilitation in schizophrenia
pp. 97-97(1)
Authors: Barch D.M.; Carter C.S.; Cohen J.D.; Hachten P.C.

Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy
pp. 98-98(1)
Authors: Barr W.B.; Bilder R.M.; Goldman R.S.; Lieberman J.A.

Inhibition of return in schizophrenia
pp. 99-99(1)
Authors: Bustillo J.; Gold J.; Thaker G.; Buchanan R.

A prospective cohort study of childhood cognitive deficits as precursors of schizophrenia
pp. 99-100(2)
Authors: Cannon T.D.; Bearden C.E.; Hollister J.M.; Hadley T.

Cognitive correlates of soft neurological signs in schizophrenia
pp. 100-100(1)
Authors: Chen E.Y.H.; Lam L.C.W.; Chen R.Y.L.; Nguyen D.G.H.

Recent hallucinators demonstrate abnormalities of central auditory processing
pp. 100-100(1)
Authors: Copolov D.; Headlam D.; Mackinnon A.; McKay C.; Thomas R.

The effects of ketamine on memory and other cognitive functions in schizophrenic patients and normal volunteers
pp. 100-100(1)
Authors: Corey P.K.; Lahti A.C.; LaPorte D.J.; Weiler M.A.; Warfel D.T.; Tamminga C.A.

Behavioral and electrophysiological correlates of attribution of malevolence to other people
pp. 101-101(1)
Authors: Debruille J.B.; Pelchat N.; Dubuc N.; Brodeur P.M.

Redundancy-associated deficit hypothesis for crossover is supported by change across trials in schizotypal males
pp. 101-101(1)
Authors: Dionisio D.P.; Sarkin A.J.; Hillix W.A.; Granholm E.L.

Why poor performance on the rivermead behavioural memory test in schizophrenia is indicative of a specific disease process
pp. 101-101(1)
Authors: Doody G.A.; Sanderson T.L.; Cunningham-Owens D.G.; Johnstone E.C.

Emotion recognition in first-episode schizophrenia: facial expression, affective prosody and emotion names
pp. 101-102(2)
Authors: Edwards J.; Pattison P.E.; Jackson H.J.; Wales R.J.

Inhibition of dominant response tendencies in schizophrenia
pp. 102-102(1)
Authors: Elvevaag B.; Duncan J.; McKenna P.J.

Primacy and recency on the Rey Auditory Verbal Learning Test (RAVLT): a comparison of normal controls and patients with schizophrenia
pp. 102-102(1)
Authors: Flashman L.A.; Torres I.J.; O'Leary D.S.; Tranel A.P.; Mosnik D.M.; Black J.; Andreasen N.C.

Longitudinal assessment of neuropsychiatric functioning in patients with schizophrenia and Alzheimer's disease
pp. 102-103(2)
Authors: Fleming K.; Nielson K.; Nilsson M.; Kalali A.; Sandman C.; Potkin S.G.; Bunney W.

Effects of clozapine and haloperidol on explicit memory in treatment refractory patients
pp. 104-104(1)
Authors: Goldman R.S.; Bates J.A.; Pappadopulos E.; Bilder R.M.; Borenstein M.; Kane J.; Schooler N.; Marder S.

Impact of genetic vulnerability and obstetric factors on cognitive development up to age 7 in offspring high risk for psychosis
pp. 104-104(1)
Authors: Goldstein J.M.; Buka S.L.; Seidman L.J.; Zornberg G.; Hang L.; Denny L.; Goldin A.; Tsuang M.T.

Effects of a computer-assisted attention training in schizophrenic patients
pp. 105-105(1)
Authors: Gorissen M.; Vollema M.; Kuipers T.; van Haren N.

Neuropsychological deficits in familial cerebellar degeneration: comparisons between psychotic and non-psychotic family members
pp. 105-105(1)
Authors: Gray N.S.; Pickup G.; Gilluley P.; Spence S.; Morton N.; James D.V.

Early visual processing deficits in remitted, unmedicated schizophrenic patients
pp. 105-106(2)
Authors: Green M.F.; Nuechterlein K.H.

Rapid and gradual reconstitutive processes in schizophrenia
pp. 106-106(1)
Authors: Haas G.L.; Sweeney J.A.; Keshavan M.S.; Schooler N.R.

Learning and recall inefficiency in schizophrenia
pp. 107-107(1)
Authors: Harris J.G.; Benetto L.; Adler L.; Freedman R.

Cognitive decline in geriatric schizophrenic inpatients
pp. 107-107(1)
Authors: Harvey P.D.; Powchik P.; Mohs R.C.; Davidson M.

Wisconsin card sorting test and EEG changes in early psychosis
pp. 107-107(1)
Authors: Hofer H.; Merlo M.C.G.; Brenner H.D.

Estrogen levels relate to neuropsychological function in female schizophrenics
pp. 107-108(2)
Authors: Hoff A.L.; Wieneke M.; Horon R.; Blankfeld H.; Espinoza S.; Faustman W.O.; Kremen W.S.; Nordahl T.

Longitudinal neuropsychological findings from Stony Brook first episode study
pp. 108-108(1)
Authors: Hoff A.L.; Wieneke M.; Horon R.; Sakuma M.; Nordahl T.; DeLisi L.E.

Response time (RT) and the odds of making a correct choice
pp. 108-108(1)
Authors: Holcomb H.H.; Li-Wan C.; Lahti A.; Zuo Z.; Medoff D.; Caudill P.J.; Weiler M.; Tamminga C.A.

Cognitive function and psychotic symptoms in geriatric schizophrenia
pp. 108-109(2)
Authors: Howanitz E.; Hwang M.; Kaplan S.; Stern R.; Harvey P.D.; Mohs R.C.; Losonczy M.

Impact of benztropine on WAIS-R performance in schizophrenia
pp. 109-109(1)
Authors: Huegel S.G.; Allen D.N.; Gurklis J.A.; Kelley M.E.; van Kammen D.P.

Memory and executive function in first episode schizophrenia
pp. 109-109(1)
Authors: Hutton S.B.; Puri B.K.; Duncan L.-J.; Robbins T.W.; Barnes T.R.E.; Joyce E.M.

Schizophrenia impairs strategy generation but spares working memory
pp. 109-109(1)
Authors: Iddon J.L.; McKenna P.J.; Sahakian B.J.; Robbins T.W.

Temporal disintegration of visual perception in schizophrenia
pp. 110-110(1)
Authors: Izawa R.; Iwawaki A.; Ohta K.; Matsushima E.; Toru M.

Self-monitoring deficits in schizophrenia: autonoetic agnosia
pp. 110-110(1)
Authors: Keefe R.S.E.; Courtney M.; McEvoy J.M.

Cerebellar and cortical sensory dysfunction in schizophrenics and their relatives: hard neurologic signs
pp. 110-110(1)
Authors: Kinney D.K.; Yurgelun-Todd D.A.; Woods B.T.

Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man
pp. 110-111(2)
Authors: Kumari V.; Corr P.J.; Mulligan O.; Cotter P.A.; Checkley S.A.; Gray J.A.

Amphetamine and cognitive impairment in schizotypal personality disorder
pp. 111-111(1)
Authors: Kirrane R.; Harvey P.D.; Cornblatt B.; Bergman A.; Siever L.J.

Heterogeneity of Wisconsin card sorting test performance in schizophrenia: a factor analytic study
pp. 111-112(2)
Authors: Koren D.; Seidman L.J.; Harrison R.H.; Lyons M.J.; Kremen W.S.; Faraone S.V.; Goldstein J.M.; Caplan B.B.; Tsuang M.T.

Neuropsychological and symptom-based evidence of dysfunction in dorsolateral and orbital frontal systems in schizophrenia
pp. 112-112(1)
Authors: Kremen W.S.; Seidman L.J.; Oscar-Berman M.; Shore A.R.; Faraone S.V.; Tsuang M.T.

Effects of monetary reinforcement on verbal and visuospatial memory in schizophrenic subjects
pp. 112-113(2)
Authors: LaPorte D.; Lahti A.; Hagedorn H.; Corey T.; Tamminga C.

Detailed neuropsychological testing in treatment resistant and treatment responsive schizophrenia
pp. 113-113(1)
Authors: Lawrie S.; Rogers A.; O'Carroll R.; Ebmeier K.; Goodwin G.; Johnstone E.

Neural network modeling of initiation and inhibition in schizophrenia
pp. 114-114(1)
Authors: Mahurin R.; Velligan D.; Miller A.

Gender differences in the relationship between neuropsychological impairment and symptom dimensions in schizophrenia
pp. 114-115(2)
Authors: Malla A.K.; Norman R.M.G.; Morrison-Stewart S.; Williamson P.C.; Helmes E.; Cortese L.

Cognitive functioning and persistently high negative symptoms in chronic schizophrenia
pp. 115-115(1)
Authors: McGlashan T.H.; Quinlan D.; Glazer W.; Schuldberg D.

Relationship between plasma cortisol and cognitive function in schizophrenia
pp. 115-115(1)
Authors: McGurk S.R.; Lee M.; Meltzer H.Y.

Memory and negative symptoms predict role play performance in schizophrenic outpatients
pp. 115-116(2)
Authors: McKee M.B.; Smith T.E.; Hull J.W.; Walsh C.A.; Guttroff L.; Ellis R.A.

EEG changes and performance in span of apprehension in patients with early psychosis
pp. 116-116(1)
Authors: Merlo M.C.G.; Hofer H.; Brenner H.D.

Unilateral olfactory functioning in patients with schizophrenia
pp. 116-117(2)
Authors: Moberg P.J.; Turetsky B.I.; Doty R.; McKeown D.; Gur R.C.; Gur R.E.

Neurological soft signs and neuropsychological performance in first episode schizophrenia
pp. 117-117(1)
Authors: Mohr F.J.; Hubmann W.; Sobizack N.; Albus M.

Intellectual function and psychopathology in offspring at risk for schizophrenia
pp. 117-117(1)
Authors: Montrose D.M.; Dick E.; Pierri J.N.; Krinsky C.; Sweeney J.A.; Keshavan M.S.

Social functioning in relation to frontal lobe impairment
pp. 118-118(1)
Authors: Moore D.A.; Park S.; Born W.

Judging disorder in schizophrenia, concept and concept objectivity
pp. 118-118(1)
Authors: Morin D.C.; Decup A.M.; Morellini A.; Cochet N.C.; Lande H.; Poirier A.M.

Factor analysis of neuropsychological data in patients with schizophrenia and normal controls
pp. 118-118(1)
Authors: Mosnik D.M.; Gold S.M.; Tranel A.P.; O'Leary D.S.; Andreasen N.C.

The mechanisms of confabulation in schizophrenia
pp. 118-119(2)
Authors: Nathaniel-James D.A.; Foong J.; Frith C.D.

Psychoacoustic investigations in schizophrenia
pp. 119-119(1)
Authors: Nielzen S.; Olsson O.

Neuropsychological function in siblings of schizophrenics
pp. 119-119(1)
Authors: Olson S.C.; Nasrallah H.A.; Bornstein R.A.

Cognitive impairment and clinical symptoms in geriatric schizophrenic patients: differences associated with overall outcome
pp. 119-120(2)
Authors: Parrella M.; Howanitz E.; Powchik P.; Mohs R.C.; Harvey P.D.

'Theory of mind' and contextual processing in schizophrenia
pp. 121-121(1)
Authors: Pickup G.J.; Frith C.D.

Cognitive and clinical correlates of inaccurate affect recognition in schizophrenia
pp. 121-121(1)
Authors: Poole J.; Corwin F.; Vinogradov S.

Cognitive correlates of the deficit syndrome in geriatric schizophrenia
pp. 122-122(1)
Authors: Putnam K.M.; Davidson M.; Harvey P.D.

Associative learning, neuropsychological performance and psychophysiologic responses in inpatient and outpatient schizophrenics
pp. 122-123(2)
Authors: Renazco M.A.; Rawls T.; Smith M.; Kaiser S.; Davis M.; Russell I.S.; Young K.A.

Factors important for remediating the WCST in schizophrenia
pp. 123-123(1)
Authors: Russell S.L.; David A.S.

Unilateral assessment of olfactory deficits in schizophrenia
pp. 123-123(1)
Authors: Rupp C.; Ilmberger J.; Oberbauer H.; Wanko C.; Scholtz A.; Hinterhuber H.

The nature of impairments on tasks of executive function in patients with schizophrenia
pp. 124-124(1)
Authors: Rushe T.M.; Woodruff P.W.R.; Murray R.M.; Morris R.G.

'Do different insight scales measure the same thing?'
pp. 124-124(1)
Authors: Sanz M.; Constable G.; Lopez-Ibor I.; Kemp R.; David A.

Ocular, cognitive and social interference in schizophrenia
pp. 124-124(1)
Authors: Schooler C.; Roberts B.; Zahn T.; Cohen R.

Self-experienced neuropsychological deficits in the mentally retarded as a possible cause of schizophrenia proneness
pp. 124-125(2)
Authors: Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Effect of nifedipine on motor skill learning in schizophrenia
pp. 125-125(1)
Authors: Schwartz B.; Fay-McCarthy M.; Kendrick K.; Rosse R.; Deutsch S.

Delayed and object alternation deficits in schizotypal personality disorder
pp. 125-125(1)
Authors: Seidman L.J.; Voglmaier M.M.; Niznikiewicz M.; Dickey C.C.; Sollinger J.; Rhoads R.; Shenton M.E.; McCarley R.W.

The use of schemas in understanding schizophrenic reasoning
pp. 125-126(2)
Authors: Simpson J.; Done J.

Symptom and neuropsychological determinants of insight in schizophrenia
pp. 126-126(1)
Authors: Smith T.E.; Hull J.W.; Walsh C.A.; Felger T.E.; Hedayat-Harris A.; Raymond S.C.; Weiss K.A.; Pappas Schattman S.S.

Effects of schizophrenia and complex partial epilepsy on memory
pp. 126-126(1)
Authors: Stone W.S.; Seidman L.J.; Jones R.; Harrison R.H.; Mirsky A.

Implicit motor learning and memory in schizophrenia
pp. 127-127(1)
Authors: Thoroughman K.A.; Weiler M.A.; Lahti A.C.; Tamminga C.A.; Holcomb H.H.

Poor perception of nonverbal social-emotional cues in relatives of schizophrenic patients: an attentional deficit?
pp. 127-127(1)
Authors: Toomey R.; Seidman L.J.; Lyons M.J.; Faraone S.V.; Tsuang M.T.

The relationship of IQ to source monitoring errors in schizophrenia
pp. 127-127(1)
Authors: Vinogradov S.; Poole J.H.; Willis-Shore J.; Ober B.A.; Shenaut G.K.

Executive and attentional functions mediate accelerated forgetting in schizophrenia
pp. 128-128(1)
Authors: Willson D.F.; Bilder R.M.; Christensen B.K.; Lieberman J.A.

The effects of D-amphetamine on working memory and language deficits in schizophrenia
pp. 129-129(1)
Authors: Barch D.M.; Carter C.S.; Braver T.S.; Cohen J.D.

Behavioral assessment of frontal/cingulate attention deficits in schizophrenia
pp. 129-129(1)
Authors: Belger A.; McNulty A.-M.; Krystal J.H.

Disturbed language processing disorganization, and attentional impairment in schizophrenia
pp. 130-130(1)
Authors: Carter C.S.; Barch D.; Cohen J.D.

Context processing disturbances in schizophrenia: empirical test of a theoretical model
pp. 130-130(1)
Authors: Cohen J.D.; Barch D.M.; Carter C.S.; Servan-Schreiber D.

Comparative affective reactivity of different types of communication disturbances in schizophrenia
pp. 131-131(1)
Authors: Docherty N.M.; Hebert A.S.; Hall M.J.; Gordinier S.W.

Attentional impairment and specific subtypes of communication deviance in schizophrenic patients
pp. 131-131(1)
Authors: Eckert S.L.; Velligan D.I.; Mahurin R.K.; Miller A.L.; Bow-Thomas C.C.

Response inhibition in formal thought disorder
pp. 131-131(1)
Authors: Gorissen M.E.E.; van Haren N.E.M.; Vollema M.G.

Semantic priming, overinclusiveness and formal thought disorder
pp. 131-132(2)
Authors: Gorissen M.E.E.; Nielen M.M.A.

Is thought disorder in schizophrenia a function of loss of context and impaired working memory?
pp. 132-132(1)
Authors: Harrow M.; Rappole K.; Sands J.R.; Jobe T.H.; Martin E.M.

Voluntary and involuntary shifts of attention in schizophrenia
pp. 132-132(1)
Authors: Hill J.M.; Sweeney J.A.; Haas G.L.

Thought disorder in subjects with schizophrenia spectrum disorders
pp. 133-133(1)
Authors: Koistinen P.; Wahlberg K.-E.; Anias-Tanner H.; Keskitalo P.; Tarvainen T.; Moring J.; Hakko H.; Wynne L.C.; Tienari P.

Semantic priming N4 modulation in formal thought disordered schizophrenics
pp. 133-134(2)
Authors: Laurent J.-P.; Passerieux C.; Lafont-Rapnouil S.; Baribeau J.; Hardy-Bayle M.-C.

Language cohesion in preschizophrenic children
pp. 134-134(1)
Authors: Leinonen E.; Done D.J.; Sinclair C.; Crow T.J.

Attention deficits in adolescents with schizophrenia or ADHD
pp. 134-134(1)
Authors: Oie M.; Rund B.R.; Sundet K.

Attentional inhibition and clinical symptoms in schizophrenia patients
pp. 134-135(2)
Authors: Park S.; Puschel J.; Minor K.; Ragin A.; Hauser B.; Hell D.

Working memory performance in relation to clinical symptoms in schizophrenia patients: a 4-month follow-up study
pp. 135-135(1)
Authors: Park S.; Puschel J.; Moore D.A.; Ragin A.; Hooker C.; Hauser B.; Hell D.

Structural and functional correlates of working memory and olfactory identification in schizotypal subjects
pp. 135-135(1)
Authors: Park S.; Raine A.; Lencz T.; Bihrle S.; LaCasse L.

Effect of stimulus meaningfulness on CPT performance
pp. 136-136(1)
Authors: Roberts B.; Schooler C.

Working memory is spared in schizophrenia
pp. 136-136(1)
Authors: Rubinsztein J.; McKenna P.J.; Baddeley A.D.

Semantic priming in deluded schizophrenics
pp. 136-136(1)
Authors: Rossell S.L.; Shapleske J.; David A.S.

Neuropsychological evidence of a deficit in switching attention in schizophrenia--a replication study
pp. 136-137(2)
Authors: Smith G.L.; Large M.M.; O'Sullivan B.T.; Kavanagh D.J.; Karayanidis F.; Michie P.T.

A cognitive neuroscience view on formal thought disorder
pp. 137-137(1)
Authors: Spitzer M.; Maier S.; Weisbrod M.

Working memory deficits in schizophrenia: dysfunction in multiple systems, not in the central executive
pp. 137-137(1)
Authors: Spindler K.A.; Sullivan E.V.; Menon V.; Lim K.O.; Pfefferbaum A.

The working memory construct: convergent and discriminant validity
pp. 137-138(2)
Authors: Strauss M.E.; Jaskiw G.; Smith R.W.; Rizzuto L.

Spatial and verbal working memory deficits in schizophrenia
pp. 138-138(1)
Authors: Taylor S.F.; Smith E.E.; Jonides J.; Decker L.; Smet I.C.; Tandon R.

Communication deviance of the adoptive parents and poor cognitive functioning of the adoptees
pp. 138-138(1)
Authors: Wahlberg K.-E.; Wynne L.C.; Keskitalo P.; Koistinen P.; Tarvainen T.; Hakko H.; Lahti I.; Laksy K.; Moring J.; Naarala M.; Sorri A.; Seitamaa M.; Tienari P.

Thalamic volumes in schizophrenia: failure to replicate reduced volume
pp. 139-139(1)
Authors: Arciniegas D.; Sheeder J.; Rojas D.; Teale P.; Reite M.

Reversed planum temporale asymmetry in schizophrenia--a replication study
pp. 139-139(1)
Authors: Barta P.E.; Pearlson G.D.; Pulver A.E.; Powers R.E.; Casanova M.; Frangou S.; Petty R.G.

Neuroanatomic abnormalities in the psychoses: diagnostic specificity or severity spectrum?
pp. 139-140(2)
Authors: Bilder R.M.; Bogerts B.; Wu H.; Strous R.; Lee H.; Lieberman J.; Woerner M.

Shape deformity in schizophrenia: a MRI morphometric study
pp. 140-140(1)
Authors: Buckley P.F.; Dean D.; Friedman L.; Kwon D.; Bookstein F.L.; Lewin J.S.; Kamath J.; Lys C.

Regional brain morphology in siblings discordant for schizophrenia: a magnetic resonance imaging study
pp. 140-140(1)
Authors: Cannon T.D.; Huttunen M.; Standertskjold-Nordenstam C.-G.; Salonen O.; Valanne L.; Lonnqvist J.

Point distribution models and gyrification in schizophrenia
pp. 140-140(1)
Authors: Caunce A.; Hopkins R.S.; Taylor C.; Lewis S.W.

Effect of neuroleptic treatment on post-mortem rodent striatal volumes
pp. 140-141(2)
Authors: Chakos M.; Lee H.; Bilder R.; Zhao M.; Tamminga C.

Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia
pp. 141-141(1)
Authors: Crandall D.T.; Szeszko P.R.; Bilder R.M.; Strous R.; Lieberman J.A.

A comparison of the hippocampus in schizophrenia and control subjects using automated methods for neuromorphometry
pp. 141-141(1)
Authors: Csernansky J.G.; Haller J.W.; Banerjee A.; Lei W.; Joshi S.; Christensen G.E.; Gado M.; Vannier M.W.; Miller M.I.

Brain structural change over time after a 1st episode of schizophrenia
pp. 141-142(2)
Authors: DeLisi L.E.; Hoff A.L.; Tew W.; Sakuma M.; Grimson R.

Landmark shape in schizophrenia: regional neuroanatomic correlates
pp. 142-142(1)
Authors: DeQuardo J.R.; Rajaprabhakaran R.; Bookstein F.L.; Brunberg J.A.; Tandon R.

Regional cerebellar volume deficits in schizophrenia, alcoholism and schizophrenia with alcohol comorbidity
pp. 142-143(2)
Authors: Deshmukh A.; Sullivan E.V.; Mathalon D.H.; Desmond J.E.; Lim K.O.; Pfefferbaum A.

Abnormal signal intensity of corpus callosum in schizophrenia
pp. 143-143(1)
Authors: Dick E.L.; Kotwal R.; Rosenberg D.R.; Bagwell W.W.; Kisler T.; Sweeney J.; Pettegrew J.W.; Keshavan M.S.

MRI and cognitive correlates in schizotypal personality disorder
pp. 143-143(1)
Authors: Dickey C.C.; Voglmaier M.M.; Shenton M.E.; Niznikiewicz M.; Seidman L.J.; Fischer I.A.; Teh E.; Rhoads R.A.; McCarley R.W.

Gender dependence of prefrontal volume in schizophrenia
pp. 143-144(2)
Authors: Doyle R.G.; Sheeder J.; Rojas D.C.; Teale P.; Simon J.; Reite M.

Cortical surface in schizophrenic patients and controls: MRI, 3-D reconstruction and in vivo morphometry
pp. 144-144(1)
Authors: Falkai P.; Schormann T.; Steinmetz H.; Palomero-Gallagher N.; Honer W.G.; Zilles K.

MRI measurements in adolescents with schizophrenia and bipolar disorder
pp. 144-144(1)
Authors: Findling R.L.; Friedman L.; Swales T.P.; Swift D.K.; Wise A.; Schulz S.C.

A study of head size in adult patients with schizophrenia
pp. 144-145(2)
Authors: Friedman L.; Jesberger J.A.; Swales T.; Rakow R.; Ward K.; Pi D.; Schulz S.C.; Buckley P.F.

Prediction of intracranial volume from post-mortem head, stature and body frame measurements: influences of gender, race, and implications for schizophrenia research
pp. 145-145(1)
Authors: Friedman L.; Cerny C.; Wiechers I.; Jellema L.; Latimer B.; Schulz S.C.; Buckley P.F.

Volumetric magnetic resonance imaging analysis of the cingulate cortex and corpus callosum in schizophrenia
pp. 145-145(1)
Authors: Garnett M.L.; Semple W.E.; Konicki P.E.; Muswick G.J.; Goyer P.F.

Premorbid functioning, symptoms and response in expanding vs non-expanding ventricle schizophrenic psychoses
pp. 145-146(2)
Authors: Garver D.L.; Christensen J.D.; Nair T.R.; Holcomb J.; Kingsbury S.J.

Sex differences in structural brain abnormalities in schizophrenia: frontal versus posterior brain regions
pp. 146-146(1)
Authors: Goldstein J.M.; Seidman L.J.; Goodman J.; Makris N.; Kennedy D.; Hoge E.; Caviness V.; Faraone S.V.; Tsuang M.T.

Verbal memory and regional brain volume in schizophrenia: MRI and neuropsychological measures
pp. 146-147(2)
Authors: Goodman J.M.; Seidman L.J.; Goldstein J.M.; Faraone S.V.; Hoge E.; Makris N.; Kennedy D.N.; Caviness V.S.; Tsuang M.T.

Uncoupling between tissue volume and metabolic rates in schizophrenia
pp. 147-147(1)
Authors: Gur R.C.; Mozley L.H.; Turetsky B.I.; Mozley P.D.; Gur R.E.

Asymmetry of the middle cranial fossa in schizophrenia, temporal lobe epilepsy and controls
pp. 147-147(1)
Authors: Hamersley S.P.; Wang E.; Regis E.; Lang D.J.; Beach T.G.; Smith G.N.; Lapointe J.S.; Falkai P.; Honer W.G.

Reduced white matter volume in schizophrenia: a controlled 3D MR segmentation study
pp. 147-148(2)
Authors: Hemmingsen R.; Madsen A.; Ring P.; Lassen A.

MRI and ERP abnormalities in first episode schizophrenia and affective psychosis
pp. 148-148(1)
Authors: Hirayasu Y.; Shenton M.E.; Salisbury D.F.; Fischer I.A.; Dickey C.D.; Arakaki H.; Yurgelun-Todd D.A.; Tohen M.; McCarley R.W.

Development of a temporal lobe task in schizophrenia
pp. 148-148(1)
Authors: Howanitz E.; Losonczy M.; Hwang M.; Schaefer C.; Sison C.

Sex and diagnostic effects on corpus callosum morphology
pp. 148-149(2)
Authors: Karp P.E.; Houwei W.; Jian H.; Bilder R.

Reduction of nucleus accumbens volume in schizophrenia: a volumetric MRI-study
pp. 149-149(1)
Authors: Kromkamp M.; Baare W.F.C.; Pol H.E.H.; van der Linden J.A.; Kahn R.S.

Morphometry of cerebellar vermis in chronic schizophrenia and autism: MRI evidence of developmental etiology
pp. 149-149(1)
Authors: Kilman A.; Reeve A.; Cooperman R.B.; Lesnik P.G.; Ciesielski K.T.

Brain anatomic magnetic resonance imaging in pediatric patients with psychosis NOS
pp. 149-150(2)
Authors: Kumra S.; Giedd J.; Jacobsen L.; McKenna K.; Frazier J.; Gordon C.; Lenane M.; Hamburger S.; Smith A.; Rapoport J.

The MRI study of cavum septi pellucidi in schizophrenia and affective disorder
pp. 150-150(1)
Authors: Jun S.K.; Shenton M.E.; Hirayasu Y.; Fischer I.A.; McCarley R.W.

Sylvian fissure and middle cranial fossae asymmetries in families with schizophrenia
pp. 150-150(1)
Authors: Lang D.J.; Bassett A.S.; Falkai P.; Smith G.N.; Lapointe J.S.; Honer W.G.

MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia
pp. 151-151(1)
Authors: Lencz T.; Redmond M.P.; Bookstein F.L.; Houwei W.; Bilder R.M.; Ashtari M.; Lieberman J.A.

Corpus callosum, behavioral lateralization, and schizophrenia
pp. 151-151(1)
Authors: Lewine R.; Levine L.; Scheller-Gilkey G.; Shurett R.; Caudle J.

Clinical symptoms and MRI abnormalities in schizophrenia and in epilepsy
pp. 151-152(2)
Authors: Marsh L.; Sullivan E.; Spears S.; Sung T.; Lim K.; Morrell M.; Pfefferbaum A.

Structural MRI abnormalities in schizophrenia: a comparison of state hospital and veterans hospital patients
pp. 152-152(1)
Authors: Marsh L.; Lim K.; Hoff A.; Harris D.; Beal M.; Minn K.; Faustman W.; Csernansky J.; Sullivan E.; Pfefferbaum A.

Longitudinal analysis of MRI brain volumes in schizophrenia
pp. 152-152(1)
Authors: Mathalon D.H.; Sullivan E.V.; Lim K.O.; Pfefferbaum A.

A structural MRI study of schizophrenia and epilepsy
pp. 152-153(2)
Authors: Mellers J.D.C.; Toone B.K.; Lishman W.A.

Progressive ventricular enlargement and neurodegerative schizophrenia
pp. 153-153(1)
Authors: Nair T.; Christensen J.; Kumar N.; Mayhew E.; Garver D.

Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study
pp. 153-153(1)
Authors: Nelson M.D.; Saykin A.J.; Flashman L.A.; Riordan H.J.

Incidence of enlarged cavum septi pellucidi in childhood onset schizophrenia vs healthy controls
pp. 153-154(2)
Authors: Nopoulos P.; Rapoport J.; Giedd J.; Andreasen N.

Structural and functional imaging in catatonia
pp. 154-154(1)
Authors: Northoff G.; Waters H.; Diekmann S.; Braus D.; Leschinger A.; Bogerts B.

Brain morphology in down syndrome and schizophrenia
pp. 154-154(1)
Authors: Pearlson G.D.; Barta P.E.; Aylward E.H.; Breiter S.; Warren A.C.

Accelerated increase brain ventricular volume at 2-year rescan for childhood onset schizophrenics
pp. 154-154(1)
Authors: Rapoport J.L.; Giedd J.; Alaghband-Rad J.; Jacobsen L.; Kumra S.; Lenane M.

The effect of cumulative neuroleptic exposure on caudate and putamen volumes
pp. 154-155(2)
Authors: Rodriguez R.; Flaum M.; Nopoulos P.

Talairach-based MRI analysis in first episode schizophrenia
pp. 155-155(1)
Authors: Roy P.D.; Zipursky R.B.; Mikulis D.E.

Application of a nearly automatic image scale space linking scheme to segment gray and white matter and intracranial volumes on MR images
pp. 155-155(1)
Authors: Schnack H.G.; Hulshoff Pol H.E.; Staal W.; Vincken K.; Niessen W.M.; Viergever M.A.; Kahn R.S.

Structural MRI studies of first-degree relatives of schizophrenic patients
pp. 155-155(1)
Authors: Seidman L.J.; Faraone S.V.; Goldstein J.M.; Matsuda G.; Hoge E.; Toomey R.; Bates J.F.; Makris N.; Kennedy D.N.; Caviness V.S.; Tsuang M.T.

Loss of sylvian fissure asymmetry in schizophrenic auditory hallucinators using structural MRI
pp. 156-156(1)
Authors: Shapleske J.; Rossell S.L.; Woodruff P.W.R.; David A.S.

Methodological considerations of measuring the planum temporale
pp. 156-156(1)
Authors: Shapleske J.; Rossell S.L.; Woodruff P.W.R.; David A.S.

Corpus callosum and schizophrenia: a five year follow-up
pp. 156-156(1)
Authors: Shurett R.B.; Lewine R.R.J.; Caudle J.

Comparison of striatal volumes in schizophrenic patients with and without eye tracking disorder
pp. 156-157(2)
Authors: Sjodin L.E.; Ross D.E.; Vladar K.; Buchanan R.W.; Thaker G.K.; Holcomb H.H.; Tamminga C.A.

Progressive brain changes and age at onset of illness in schizophrenia
pp. 157-157(1)
Authors: Smith G.N.; Kopala L.C.; Lapointe J.S.; MacEwan G.W.; Altman S.; Flynn S.W.; Schneider T.; Falkai P.; Honer W.G.

Stereological estimation of gyrification index and related measures of cortical folding from mr data in schizophrenia
pp. 157-157(1)
Authors: Stefan M.D.; Sharma T.; Ellison Z.; Murray R.; Everall I.

Pregnancy and birth complications (PBC)--associated hippocampal volume reduction in sporadic schizophrenia
pp. 157-158(2)
Authors: Stefanis N.; Yakeley J.; Frangou S.; Sharma T.; O'Connell P.; Morgan K.; Murray R.

Parcellation of the frontal lobes in first-episode schizophrenia
pp. 158-158(1)
Authors: Szeszko P.; Lencz T.; Bilder R.; Redmond M.; Wu H.; Lieberman J.

Temporal origin of cerebral structural abnormalities in schizophrenia: associations with second trimester dermatoglyphic ridge counts
pp. 158-158(1)
Authors: van Os J.; Woodruff P.; Fananas L.; Shuriquie N.; Howard R.; Murray R.

Reduced frontal volume, frontal-temporal connectivity, and hippocampal volume is associated with the deficit syndrome in schizophrenia
pp. 158-159(2)
Authors: Ventura J.; Bartzokis G.; Nuechterlein K.H.; Subotnik K.L.; Raja P.

Prefrontal cortex in schizophrenia: a magnetic resonance imaging study using anatomically relevant landmarks
pp. 159-159(1)
Authors: Vladar K.; Buchanan R.W.; Carpenter W.T.; Barta P.E.; Pearlson G.D.

MRI-determined brain volumes and schizotypal characteristics in subjects with sex chromosome anomalies and matched controls
pp. 159-159(1)
Authors: Warwick M.M.; Best J.J.K.; Johnstone E.C.; Kestelman I.N.; Sandler R.

Change in basal ganglia volume across time in patients with schizophrenia: effects of atypical vs. typical neuroleptics
pp. 159-160(2)
Authors: Westmoreland P.; Nopoulos P.C.; Arndt S.V.; Bailey J.; Andreasen N.C.

Obstetric complications and brain MRI findings in schizophrenia
pp. 160-160(1)
Authors: Woerner M.G.; Gunduz H.; Alvir J.M.J.; Bilder R.; Lieberman J.A.

Mapping of gray matter changes in schizophrenia
pp. 160-160(1)
Authors: Wright I.; Ellison Z.; Sharma T.; Friston K.; Murray R.; McGuire P.

Absence of overall cortical and subcortical volume differences among major mental disorders
pp. 160-161(2)
Authors: Houwei W.; Young L.; Bogerts B.; Lieberman J.A.; Bilder R.M.

Shape analysis of hippocampus in schizophrenia
pp. 161-161(1)
Authors: Houwei W.; Strous R.; Bilder R.M.; Alvir J.; Ashtari M.

Volumetric MRI study of first episode schizophrenia
pp. 161-161(1)
Authors: Zipursky R.B.; Lambe E.K.; Kapur S.; Mikulis D.J.

Activation of prefronal cortex by the representation and maintainance of context information
pp. 163-163(1)
Authors: Barch D.M.; Braver T.S.; Nystrom L.; Noll D.C.; Cohen J.D.

Positron emission tomography in schizophrenics treated with atypical and typical neuroleptics
pp. 163-163(1)
Authors: Buchsbaum M.; Hazlett E.; Bark N.; Gupta A.; Fallon J.; Guich S.; Haznedar M.

How many subjects? A Monte Carlo bootstrap simulation for functional imaging
pp. 164-164(1)
Authors: Chen L.-W.; Zuo Z.; Medoff D.; Holcomb H.H.; Lahti A.C.; Tamminga C.A.

Pet correlational studies of auditory stimulation and auditory hallucinations in schizophrenia patients
pp. 164-164(1)
Authors: Copolov D.L.; Egan G.F.; Wong M.T.H.; Maruff P.; Tochon-Danguy H.J.; Chan J.G.; Waite M.

Overt and covert verbal fluency: an fMRI comparison
pp. 164-165(2)
Authors: Curtis V.; Bullmore E.; Brammer M.; Grasby P.; Murray R.; McGuire P.

Reduced cerebral response to verbal fluency tasks in schizophrenia: an fMRI investigation
pp. 165-165(1)
Authors: Curtis V.; Bullmore E.; McGuire P.; Brammer M.; Simmons A.; Grasby P.; Sharma T.; Murray R.

Relationship between symptom dimensions and cerebral blood flow in schizophrenia as assessed by 15H2O P.E.T.
pp. 165-165(1)
Authors: Flaum M.; O'Leary D.S.; Johnson D.; Arndt S.; Cizadlo T.; Hichwa R.; Andreasen N.C.

Disorganisation and frontal blood flow measured by 99mTc-HMPAO
pp. 165-165(1)
Authors: Gracia R.; Aguilar E.J.; Cejas R.; Herreros O.; Diaz A.; Hernandez J.; Fernandez L.

SPECT and schizophrenia: a comparison between medicated and non-medicated patients
pp. 166-166(1)
Authors: Gracia R.; Herreros O.; Cejas R.; Diaz A.; Fernandez L.; Hernandez J.; Aguilar E.J.

Out loud vs. silent verbal fluency: a FMRI study
pp. 166-166(1)
Authors: Gruber S.A.; Baird A.A.; Sherwood A.R.; Renshaw P.F.; Yurgelun-Todd D.A.

Ketamine induced cerebellar-cingulate rCBF correlations and rCBF patterns in normal volunteers (NV) and schizophrenic patients (SZ)
pp. 166-166(1)
Authors: Holcomb H.H.; Lahti A.; Medoff D.; Zuo Z.; Weiler M.; Corey P.; Warfel D.; Tamminga C.A.

Cerebral glucose metabolism in childhood onset schizophrenia
pp. 166-167(2)
Authors: Jacobsen L.K.; Hamburger S.D.; Van Horn J.D.; Vaituzis A.C.; McKenna K.; Frazier J.A.; Gordon C.T.; Lenane M.C.; Rapoport J.L.; Zametkin A.J.

'Typical' vs. 'atypical': lessons from pet studies of 5-HT2 and D2 occupancy of antipsychotics
pp. 167-167(1)
Authors: Kapur S.; Remington G.; Jones C.; Houle S.; Zipursky R.

Blood flow activation differences during an auditory task in schizophrenic patients with and without primary negative symptoms
pp. 167-167(1)
Authors: Lahti A.C.; Holcomb H.H.; Carpenter W.T.; Zhao M.; Buchanan R.W.; Tamminga C.A.

Regional correlations between ketamine-induced actions on psychosis and regional cerebral blood flow (rCBF)
pp. 167-168(2)
Authors: Lahti A.C.; Holcomb H.H.; Weiler M.A.; Zhao M.; Medoff D.; Chen L.-W.; Tamminga C.A.

The functional anatomy of language processing: towards an understanding of schizophrenic thought disorder
pp. 168-168(1)
Authors: Kuperberg G.R.; McGuire P.K.; Bullmore E.T.; Brammer M.J.; Wright I.C.; Williams S.C.R.; Simmons A.; David A.S.

Functional connectivity during word generation in schizophrenia
pp. 168-168(1)
Authors: Liddle P.F.; Passmore M.; Friston K.J.; Frith C.D.

Impaired secondary and tertiary olfactory processing in schizophrenia: a spect study of neuroactivation with the upsit
pp. 168-169(2)
Authors: Malaspina D.; Lignelli A.; Pererra G.; Marshall R.; Gorman J.; Van Heertum R.

Brain activity during stimulus independent thought
pp. 169-169(1)
Authors: McGuire P.; Paulesu E.; Frackowiak R.; Frith C.

A pet study of formal thought disorder
pp. 169-169(1)
Authors: McGuire P.; Quested D.; Spence S.; Murray R.; Frith C.; Liddle P.

The methodological effects of repeated [15]O pet blood flow scans in schizophrenic and normal volunteers during rest and task performance
pp. 169-169(1)
Authors: Medoff D.R.; Holcomb H.H.; Lahti A.C.; Zhao Z.; Chen L.-W.; Tamminga C.A.

An fMRI study of verbal working memory in schizophrenia
pp. 169-170(2)
Authors: Mellers J.D.C.; Wykes T.; Bullmore E.; Williams S.C.R.; Simmons A.; Reeder C.; Corner J.; Brammer M.

Regional cerebral glucose metabolic differences via the PET-600 in paranoid schizophrenics performing a stroop task
pp. 170-170(1)
Authors: Nordahl T.E.; Kusubov N.; Carter C.; Kraft L.; Salamat S.; Baldo J.; Robertson L.

A pet study of auditory attention deficits in patients with schizophrenia: a replication and extension of previous findings
pp. 170-170(1)
Authors: O'Leary D.S.; Andreasen N.C.; Hurtig R.R.; Arndt S.; Flaum M.A.; Hichwa R.D.

Functional neuroanatomy of working memory and attention in schizophrenia
pp. 170-171(2)
Authors: O'Sullivan B.T.; Smith G.L.; Woodham B.L.; Large M.M.; Kavanagh D.J.; Watson J.D.; Michie P.T.; Karayanidis F.

Verbal fluency (VF) and brain evoked potentials in schizophrenia
pp. 171-171(1)
Authors: Robins N.M.; Chen A.C.N.; Soni S.D.; Deakin J.F.W.

Sex-specificity of cerebral asymmetry in heschl's gyrus in paranoid schizophrenia
pp. 171-172(2)
Authors: Rojas D.; Teale P.; Sheeder J.; Simon J.; Reite M.

Functional neuroanatomy of smooth pursuit eye movements in normal controls and schizophrenic patients
pp. 172-172(1)
Authors: Ross D.E.; Holcomb H.H.; Thaker G.K.; Buchanan R.; Medoff D.R.; Tamminga C.A.

Sensorimotor cortex and supplementary motor area changes in schizophrenia: studies with functional magnetic resonance imaging
pp. 172-172(1)
Authors: Schroder J.; Schad L.R.; Jahn T.; Gerdssen I.; Wenz F.; Linke A.; Baudendistel K.; Knopp M.V.

Functional MRI of attention in relatives of schizophrenic patients
pp. 172-172(1)
Authors: Seidman L.J.; Goldstein J.M.; Breiter H.C.; Goodman J.M.; Ward M.; Woodruff P.; Faraone S.V.; Kennedy D.N.; Weisskoff R.M.; Rosen B.R.; Tsuang M.T.

The effect of an atypical antipsychotic (risperidone) on temporal lobe and prefrontal cortex activity in schizophrenia
pp. 173-173(1)
Authors: Speer A.M.; Risch S.C.; Hammer M.B.; Molloy M.; Ulmer H.G.; De Vane C.L.; Vincent D.J.; George M.S.

A pet study of word generation in obligate carriers of the predisposition to schizophrenia
pp. 173-173(1)
Authors: Spence S.A.; Sharma T.; Hellewell J.; Stefan M.; Grasby P.; Deakin B.; Murray R.; Frith C.; Liddle P.

Altered lateralisation of auditory cortical response to external speech in schizophrenia
pp. 173-173(1)
Authors: Woodruff P.W.R.; Wright I.C.; Brammer M.; Bullmore E.T.; Howard R.; David A.S.; Shapleski J.; Rossell S.; Andrew C.; Williams S.C.R.; Murray R.M.

FMRI of schizophrenics and normal controls during verbal recall
pp. 174-174(1)
Authors: Yurgelun-Todd D.A.; Baird A.A.; Gruber S.A.; Cohen B.M.; Renshaw P.F.

Ketamine induced time effect by principal component analysis
pp. 174-174(1)
Authors: Zhao Z.; Holcomb H.H.; Lahti A.C.; Chen L.-W.; Medoff D.; Tamminga C.A.

SPECT measurement of human striatal synaptic dopamine concentration with [123I]IBZM
pp. 175-175(1)
Authors: Abi-Dargham A.; Kegeles L.; Malaspina D.; Clark S.; Gorman J.; Mann J.; van Heertum R.; Laruelle M.

Multivariate cluster analysis of dynamic [I-123]-IBZM SPET dopamine D2 receptor images in schizophrenia
pp. 175-175(1)
Authors: Acton P.D.; Pilowsky L.S.; Costa D.C.; Ell P.J.

Preliminary assessment of cortical GABA levels in schizophrenics using magnetic resonance spectroscopy
pp. 175-176(2)
Authors: Behar K.; Rothman D.; D'Souza D.C.; Gil R.; Petroff O.; Abi-Saab D.; Zuzarte E.; Hooten M.; Petrakis I.; Sernyak M.; White J.; Webb E.; Charney D.; Krystal J.

Brain DOPA-decarboxylase (DDC) activity in unmedicated schizophrenic patients
pp. 176-176(1)
Authors: Benkelfat C.; Nishizawa S.; Kuwabara H.; Lal S.; Chouinard G.; Cumming P.; Labelle A.; Joober R.; Bruce K.; Diksic M.; Gjedde A.

Assessment of synaptic dopamine concentrations in schizophrenia with PET
pp. 176-176(1)
Authors: Breier A.; Su T.-P.; Saunders R.; Carson R.E.; Kolachana B.S.; Weisenfeld N.; Malhotra A.K.; Elman I.; Eckelman W.C.; Pickar D.

5-HT2A receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: single photon emission tomography (SPET) findings
pp. 176-177(2)
Authors: Busatto G.F.; Travis M.J.; Pilowsky L.S.; Costa D.C.; Mulligan R.; Mertens J.; Terriere D.; Ell P.J.; Acton P.; Gacinovic S.; Okocha C.; Leysen J.E.; Kerwin R.W.

Proton magnetic resonance spectroscopy (1H MRS) of pons and cerebellum in schizophrenic patients
pp. 177-177(1)
Authors: Eluri R.; Boyko O.B.; Paul C.R.; Roemer R.A.

The maudsley early onset schizophrenia study: brain structural and maturational abnormalities in schizophrenic adolescents
pp. 177-177(1)
Authors: Frangou S.; Simmons A.; Andrews C.; Clover A.; Williams S.; Pipe R.; Murray R.M.

Hemispheric asymmetry of benzodiazepine receptor binding sites in schizophrenia--a study with 123I-iomazenil-SPECT
pp. 177-178(2)
Authors: Gerdsen I.; Pinkert J.; Oehme L.; Ripke B.; Zoephel K.; Neumann U.; Bach O.; Franke W.G.

5HT2 and D2 receptor occupancy of ziprasidone in healthy volunteers
pp. 178-178(1)
Authors: Gunn K.P.; Miceli J.J.; Rubin R.H.; Frackowiak R.S.J.; Williams S.A.; Fischman A.

D1-dopamine receptors in schizophrenia examined by PET
pp. 178-179(2)
Authors: Karlsson P.; Farde L.; Halldin C.; Sedvall G.

Hippocampal proton magnetic resonance spectroscopy (MRS) study in schizophrenia
pp. 179-179(1)
Authors: Kegeles L.S.; Shungu D.C.; Chan S.; Malaspina D.; Mann J.J.; Gorman J.M.; Kaufmann C.A.

In vivo evaluation of dopamine synaptic function in untreated schizophrenic patients
pp. 179-179(1)
Authors: Laruelle M.; Abi-Dargham A.; Krystal J.H.; Charney D.S.; Innis R.B.

Proton spectroscopy reveals normal NAA concentration in cortical gray matter in schizophrenic patients
pp. 179-180(2)
Authors: Lim K.O.; Adalsteinsson E.; Spielman D.; Sullivan E.V.; Pfefferbaum A.

Alteration in Cho/Cre in the left temporal lobe of chronic schizophrenics
pp. 180-180(1)
Authors: Moore C.M.; Bonello C.M.; Sherwood A.R.; Cohen B.M.; Renshaw P.F.; Yurgelun-Todd D.A.

A 123I IBZM spet study of striatal D2 receptors in sertindole treated patients
pp. 180-181(2)
Authors: Pilowsky L.S.; O'Connell P.; Davies N.; Busatto G.F.; Costa D.C.; Ell P.J.; Kerwin R.W.

Preliminary report: effects of clozapine and typical antipsychotics on striatal and limbic dopamine D2/D2-like receptors in vivo by 123I epidepride spet
pp. 181-181(1)
Authors: Pilowsky L.S.; Mulligan R.S.; Acton P.D.; Gacinovic S.; Busatto G.F.; Kessler R.M.; Ell P.J.; Travis M.J.; Bigliani V.; Stephenson C.; Costa D.C.; Kerwin R.W.

Striatal D2 receptor binding in olanzapine treated patients estimated by 123I IBZM spet (single photon emission tomography).
pp. 181-181(1)
Authors: Pilowsky L.S.; Busatto G.F.; Taylor M.; Costa D.C.; Sharma T.; Sigmundssen T.; Ell P.J.; Nohria V.; Kerwin R.W.

NAA/Cre ratio correlates with verbal memory
pp. 182-182(1)
Authors: Sherwood A.R.; Gruber S.A.; Moore C.M.; Yurgelun-Todd D.A.

Frontal lobe in vivo proton magnetic resonance spectroscopy in schizophrenic patients with negative symptoms
pp. 182-182(1)
Authors: Sigmundsson T.; Toone B.K.; Maier M.; Williams S.C.R.; Simmons A.; Greenwood K.; Ron M.A.

Medial prefrontal 1H MRS findings in never-treated schizophrenics and healthy controls
pp. 182-182(1)
Authors: Williamson P.C.; Bartha R.; Drost D.J.; Malla A.; Carr T.J.; Cortese L.; MacFabe G.C.; Rylett R.J.; Neufeld W.R.J.

Multiple lines of evidence for dopamine dysfunction in psychosis by imaging
pp. 183-183(1)
Authors: Wong D.F.; Gjedde A.; Reith J.; Grunder G.; Szymanski S.; Yokoi F.; Hong C.; Nestadt G.; Neufeld K.; Pearlson G.; Tune L.; Angrist B.

A comparison of two atypical antipsychotics in treatment resistant schizoprehnia
pp. 185-185(1)
Authors: Flynn S.W.; MacEwan G.W.; Altman S.; Kopala L.C.; Smith G.N.; Honer W.G.

Pimozide augmentation for the treatment of partial responders to clozapine
pp. 185-185(1)
Authors: Joseph I.; Friedman M.D.; Ault R.N.K.; Powchik M.D.P.

Treatment of clozapine-induced weight gain with phenylpropanolamine
pp. 185-186(2)
Authors: Borovicka M.C.; Fuller M.A.; Konicki P.E.; Brescan D.; Popli A.; Jurjus G.; Kong K.; Steele V.; White J.; Jaskiw G.E.

A pharmacoeconomic analysis of clozapine therapy in treatment-refractory schizophrenia
pp. 186-186(1)
Authors: Konicki P.E.; Manuel M.; Kwon K.; Jurjus G.; Jaskiw G.E.

Clozapine treatment in neuroleptic resistant schizophrenia in Barbados
pp. 186-187(2)
Authors: Malesu R.R.; Harding S.

Effectiveness of clozapine in treatment resistant schizophrenia
pp. 187-187(1)
Authors: Marder S.R.; Kane J.M.; Schooler N.R.; Wirshing W.C.; Baker R.; Ames D.; Umbricht D.; Ganguli R.; Borenstein M.

Remediation of neuropsychological impairments with clozapine
pp. 187-187(1)
Authors: Mortimer A.M.; Dye S.

Clinical and brain imaging effects of adjunctive high dose glycine with clozapine in schizophrenia
pp. 187-188(2)
Authors: Potkin S.G.; Yi J.; Bunney B.; Gulasekaram B.; Costa J.; Keator D.B.; Telford J.; Wu J.C.; Najafi A.; Bunney W.E.

Clozapine enhances neurocognition and clinical symptoms more than standard neuroleptics
pp. 188-188(1)
Authors: Potkin S.G.; Fleming K.; Telford J.; Costa J.; Gulasekaram B.; Yi J.

A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine
pp. 188-188(1)
Authors: VA CSHS17 Study Group; Rosenheck R.; Charney D.; Cramer J.; Weichun X.; Thomas J.

First improvement with clozapine: how patient should we be?
pp. 188-188(1)
Authors: Schooler N.; Borenstein M.; Ames D.; Baker R.; Umbricht D.; Wirshing W.; Kane J.; Marder S.

Effects of clozapine on cognitive functions in treatment-refractory schizophrenia
pp. 188-189(2)
Authors: Stone W.S.; Seidman L.J.; Kalinowski A.; Shagrin B.; Patel J.K.; Shafa R.; Canuso C.; Schildkraut J.J.; Green A.I.

Predictors of response to clozapine in a long-term double blind treatment study
pp. 189-189(1)
Authors: Umbricht D.; Ames D.; Wirshing W.C.; Baker R.; Chengappa R.; Borenstein M.; Schooler N.; Marder S.; Kane J.

Olanzapine response in therapy-refractory schizophrenia with substance abuse (SA)
pp. 190-190(1)
Authors: Conley R.; Gale E.; Hirsch K.

Olanzapine vs. chlorpromazine in therapy-refractory schizophrenia
pp. 190-190(1)
Authors: Conley R.R.; Tamminga C.A.; Beasley C.

The efficacy of olanzapine treatment in patients previously treated with clozapine
pp. 190-190(1)
Authors: Lingle J.S.; Peszke M.A.; Kent D.; Conley R.

Treatment failure with clozapine: can olanzapine be the alternative therapy?
pp. 191-191(1)
Authors: Tollefson G.D.; Tran P.V.; Birkett M.; Shoshani D.

Olanzapine versus risperidone in the treatment of psychosis. Preliminary report
pp. 191-192(2)
Authors: Tollefson G.D.; Tran P.V.; Hamilton S.; Kuntz A.

The course of primary and secondary negative symptoms in a controlled trial with olanzapine
pp. 192-192(1)
Authors: Tollefson G.D.; Sanger T.M.; Beasley C.M.

Comorbid mood disturbance in schizophrenia
pp. 192-192(1)
Authors: Tollefson G.D.; Lu Y.

Olanzapine in the treatment of schizoaffective disorder
pp. 192-193(2)
Authors: Tollefson G.D.; Lu Y.; Sanger T.M.; Beasley C.M.; Tran P.V.

Olanzapine versus haloperidol in the treatment of first episode psychosis
pp. 193-193(1)
Authors: Tollefson G.D.; Sanger T.M.; Lieberman J.A.

Efficacy of risperidone in first-episode schizophrenia
pp. 193-193(1)
Authors: Ahmed S.; Schooler N.; Montrose D.; Haas G.; Sweeney J.; Keshavan M.S.

Risperidone vs. haloperidol in treatment resistant schizophrenia
pp. 193-194(2)
Authors: Ames D.; Wirshing W.C.; Marshall B.D.; Green M.F.; McGurk S.R.; Mintz J.; Marder S.R.

Risperidone for first episode schizophrenia: symptom response to lower, intermediate and higher dose strategies
pp. 194-194(1)
Authors: Kopala L.C.; Good K.P.; Fredrikson D.; Whitehorn D.; Lazier L.; Honer W.G.

Risperidone treatment in polydipsia and intermittent hyponatremia
pp. 194-195(2)
Authors: Leadbetter R.A.; Shutty M.S.; Pavalonis D.; Higgins P.

Psychopathological and neuropsychological profile of clozapine vs. risperidone in refractory schizophrenics
pp. 195-195(1)
Authors: Lindenmayer J.-P.; Iskander A.; Park M.; Smith R.; Apergi F.-S.; Czobor P.

Risperidone versus haloperidol in a prospective longitudinal follow-up of recent-onset schizophrenia
pp. 195-195(1)
Authors: Miller D.D.; Ziebell S.; Nopoulos P.; Andreasen N.C.

The use of risperidone in preadolescent children
pp. 195-196(2)
Authors: Nasrallah H.A.; Gehm N.M.; Votolato N.

Pilot study of atypical antipsychotic agents in first episode schizophrenia
pp. 196-196(1)
Authors: Robinson D.G.; Lieberman J.A.; Sheitman B.; Alvir J.M.J.; Kane J.M.

The long-term efficacy and safety of 'Seroquel' (quetiapine)
pp. 196-197(2)
Authors: Arvanitis L.A.; Rak I.W.

The neurocognitive effects of quetiapine ('Seroquel', ICI 204,636)
pp. 197-197(1)
Authors: Fleming K.; Kalali A.; Chio Y.; Vargo D.L.; Thyrum P.T.; Potkin S.G.

In vitro prediction of potential metabolic drug interactions for Seroquel
pp. 198-198(1)
Authors: Grimm S.W.; Stams K.R.; Bui K.

Patients' satisfaction with and acceptability of Seroquel
pp. 198-199(2)
Authors: Kalali A.H.; Potkin S.G.

Pharmacokinetics and safety of lithium co-administered with 'Seroquel' (quetiapine)
pp. 199-199(1)
Authors: Potkin S.G.; Thyrum P.T.; Bera R.; Vargo D.; Carreon D.; Kalali A.; Maguire G.; Chiao Y.; Ewing B.J.; Wong Y.W.J.

Overview of the efficacy of 'Seroquel' (quetiapine)
pp. 199-199(1)
Authors: Rak I.W.; Arvanitis L.A.

Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in elderly psychotic patients
pp. 199-200(2)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in schizophrenic men and women
pp. 200-200(1)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

Pharmacokinetics of 'Seroquel' (quetiapine) in hepatic and renal insufficiency
pp. 200-200(1)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

The effect of phenytoin and cimetidine on the pharmacokinetics of Seroquel
pp. 200-201(2)
Authors: Wong Y.W.J.; Ewing B.J.; Thyrum P.T.; Chiao Y.

The safety and tolerability of sertindole in elderly patients with dementia
pp. 201-201(1)
Authors: Buckley P.; Cutler N.; Silber C.; O'Neil J.; Mack R.

Reduction of hospital days in sertindole treated patients: one year findings
pp. 201-202(2)
Authors: Ereshefsky L.; Nabulsi A.; Silber C.; Mack R.

Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia
pp. 202-202(1)
Authors: Granneman R.; Wozniak P.; Tran-Johnson T.; Silber C.; Mack R.

The action of sertindole on negative symptoms in schizophrenia
pp. 202-202(1)
Authors: Lahti A.; Silber C.; Mack R.

The long term cardiovascular safety of sertindole
pp. 202-202(1)
Authors: Ramirez L.; Silber C.; Mack R.

The atypical antipsychotic sertindole: a case series
pp. 203-203(1)
Authors: Suppes T.; Lee A.; Paul B.; Sanchez B.; Mack R.

Comparing sertindole clinical data and patients across the oceans
pp. 203-203(1)
Authors: Wehnert A.; van der Burght M.; Sloth-Nielsen M.

A rapid tranquillization protocol
pp. 204-204(1)
Authors: Ainsworth C.; Catts S.V.

Obstetric complications predict treatment response in first episode schizophrenia
pp. 204-205(2)
Authors: Alvir J.M.J.; Woerner M.G.; Gunduz H.; Lieberman J.A.

Compliance with maintenance medication in first-episode schizophrenia
pp. 205-205(1)
Authors: Barnes T.R.E.; McPhillips M.A.; Hillier R.; Puri B.K.; Joyce E.

Satisfaction with treatment outcome and noncompliance in schizophrenia
pp. 205-205(1)
Authors: Blyler C.R.; Fenton W.S.

Methylphenidate treatment of negative symptoms in schizophrenia
pp. 205-206(2)
Authors: Brescan D.W.; Jaskiw G.E.; Konicki P.E.

Evaluating ability to consent in psychotic inpatients
pp. 206-206(1)
Authors: Conley R.R.; Zaremba S.; McMullen R.; Love R.

Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patients
pp. 206-206(1)
Authors: Diaz E.; Levine H.B.; Sullivan M.C.; Sernyak M.J.; Hawkins K.A.; Cramer J.A.; Woods S.W.

Dose reduction in patients with schizophrenia receiving very high doses of typical antipsychotic drugs
pp. 206-207(2)
Authors: Fuller M.A.; Konicki P.E.; Borovicka M.C.; Jurjus G.; Popli A.; Brescan D.; Kwon K.Y.; Jaskiw G.E.

Selection bias in clinical trials with antipsychotics
pp. 207-207(1)
Authors: Hummer M.; Kurz M.; Kohl C.; Walch T.; Fleischhacker W.W.

The treatment of schizophrenia with partial dopamine agonist: a promising strategy
pp. 207-207(1)
Authors: Lahti A.C.; Lahti R.A.; Carlsson A.; Tamminga C.A.

The effect of nifedipine on akathisia and agitation in patients with movement disorders
pp. 208-208(1)
Authors: McCarthy M.F.; Kendrick K.A.; Rosse R.B.; Schwartz B.L.; Peace T.; Wyatt R.J.; Deutsch S.I.

Is early intervention effective and cost effective?
pp. 208-208(1)
Authors: McGorry P.D.; Edwards J.; Mihalopoulos C.; Jackson H.

Very low dose neuroleptic-treatment of first episode psychosis--is it feasible in routine clinical care?
pp. 208-208(1)
Authors: McGorry P.D.; Cocks J.; Longley T.; Webster K.; Elkins K.; Hallgren M.; Plowright D.

The use of sodium valproate to treat post-psychotic depression
pp. 208-209(2)
Authors: Mikhnyak S.I.; Vlokh I.Y.

Fatty acid supplementation in schizophrenic patients
pp. 209-209(1)
Authors: Peet M.; Laugharne J.D.E.; Ahluwalia N.; Mellor J.

Glycine transport inhibitors: A new class of antipsychotics?
pp. 211-211(1)
Authors: Borden L.A.; Bell S.C.; Ognyanov V.I.; Albert V.R.; Zhang J.; De Vivo M.; Yokoyama M.; Xie X.; Berger T.; Gerhardt G.; McKelvy J.F.

CNS catecholamines and cognitive dysfunction in schizophrenia
pp. 211-211(1)
Authors: Carter C.S.; Barch D.; Cohen J.D.; Braver T.

Antisaccade, clinical and motor executive functions in schizophrenia: effects of 5HT2 antagonist; cyproheptadine
pp. 212-212(1)
Authors: Chaudhry I.B.; Soni S.D.; Hellewell J.S.E.; Deakin J.F.W.

Attention, clinical symptoms and pharmacology in schizophrenia
pp. 212-213(2)
Authors: Cornblatt B.; Obuchowski M.; Andreasen A.

Glycine ketamine interactions in healthy humans
pp. 213-213(1)
Authors: D'Souza D.C.; Gil R.; Zuzarte E.; Abi-Saab D.; Damon D.; White J.; Zimmerman L.; Krystal J.

Tetrahydrocannabinol effects in schizophrenic subjects & healthy controls
pp. 213-213(1)
Authors: D'Souza D.C.; Gil R.; Zuzarte E.; Zimmerman L.; Abi-Saab D.; Damon D.; White J.; Sernyak M.; Krystal J.

The effects of clozapine on plasma norepinephrine kinetics in schizophrenic patients
pp. 214-214(1)
Authors: Elman I.; Goldstein D.S.; Holmes C.; Adler C.; Pickar D.; Breier A.

Risperidone's effects on verbal working memory
pp. 214-214(1)
Authors: Green M.F.; Marshall B.D.; Wirshing W.C.; Ames D.; Marder S.R.; McGurk S.; Kern R.S.; Mintz J.

Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action
pp. 214-214(1)
Authors: Horrobin D.F.; Glen A.I.M.; Cantrill R.C.

Risperidone vs. haloperidol on reaction time and fine motor speed
pp. 215-215(1)
Authors: Kern R.S.; Green M.F.; Marshall B.D.; Wirshing W.C.; Ames D.; Marder S.R.; McGurk S.; Mintz J.

The NMDA receptor and schizophrenia: from phenotype to genotype
pp. 215-215(1)
Authors: Malhotra A.K.; Breier A.; Buchanan R.; Goldman D.; Pickar D.

Dose-dependent insulin-induced increases in memory performance in healthy humans
pp. 215-216(2)
Authors: Newcomer J.W.; Coleman J.; Bhargava N.; Selke G.; Kelly A.; White D.

Predicting clozapine response: systematic evaluation of allelic variation in candidate genes
pp. 216-216(1)
Authors: Pickar D.; Goldman D.; Buchanan R.; Breier A.; Malhotra A.K.

Valproate and force control during clozapine treatment in schizophrenic patients
pp. 216-216(1)
Authors: Popli A.P.; Jaskiw G.E.; Vrtunski P.B.

Assessment and interpretation of noncompliance with oral haloperidol
pp. 217-217(1)
Authors: Radomsky E.D.; Perel J.M.; Gurklis J.A.; van Kammen D.P.

The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers
pp. 217-218(2)
Authors: Van Berckel B.N.M.; Lipsch C.; Gispen-de Wied C.; Wynne H.J.; Blankenstein R.A.; van Ree J.M.; Kahn R.S.

Dose-related ethanol effects in schizophrenic patients
pp. 218-218(1)
Authors: Zuzarte E.; D'Souza D.C.; Gil R.; Genovese A.; White J.; Charney D.S.; Krystal J.H.

Evaluation of lorazepam blockade of m-chlorophenylpiperazine (MCPP) effects in schizophrenia
pp. 218-218(1)
Authors: Zuzarte E.; D'Souza D.C.; Gil R.; White J.; AbiSaab D.; Charney D.S.; Krystal J.H.

Cognitive behavioral treatment of panic attacks in chronic schizophrenia
pp. 219-219(1)
Authors: Arlow P.B.; Moran M.E.; Bermanzohn P.C.; Siris S.G.

Cognitive impairment and work behavior in schizophrenia
pp. 219-219(1)
Authors: Bell M.; Kaplan E.A.; Bryson G.

Quality of life in first episode schizophrenia/schizophreniform disorder
pp. 219-220(2)
Authors: Browne S.; Gervin M.; Lane A.; Morris M.; Larkin C.; Waddington J.L.; O'Callaghan E.

The port pharmacological treatment recommendations
pp. 220-220(1)
Authors: Buchanan R.W.; Zito J.; Lyles A.; Lehman A.F.

PQCSPI, an instrument to measure the perception of quality of care for psychotic inpatients
pp. 220-220(1)
Authors: De Hert M.; Abrahams F.; Van Bouwel L.; Peuskens J.

Informal caregivers and schizophrenia: a pilot study
pp. 221-221(1)
Authors: Dharwadkar N.; Kulkarni J.

Adherence to schizophrenia port family treatment recommendations
pp. 221-221(1)
Authors: Dixon L.; Scott J.; Lyles A.; Fahey M.; Skinner A.; Shore A.

Quality of subjective life experience in schizophrenia-spectrum disorders
pp. 221-221(1)
Authors: Dott S.G.; Walling D.P.

Predicting rehabilitation outcome in schizophrenia
pp. 221-222(2)
Authors: Ferdinandi A.; Pollack S.; Bermanzohn P.C.

Successful vocational functioning in schizophrenia
pp. 222-222(1)
Authors: Gold J.M.; Bryant N.L.; Vladar K.; Buchanan R.W.

Disseminating treatment recommendations from the schizophrenia P.O.R.T.
pp. 222-222(1)
Authors: Goldman H.H.; McGlynn E.A.

Quality of life in schizophrenia: affiliative and instrumental domains
pp. 222-222(1)
Authors: Goodman M.S.; Hull J.W.; Terkelsen K.G.; Smith T.E.

Quality of life in schizophrenia: symptom, insight and neuropsychological determinants
pp. 223-223(1)
Authors: Goodman M.S.; Smith T.E.; Hull J.W.; Felger T.E.; Hedayat-Harris A.; Walsh C.A.; Raymond S.C.; Weiss K.A.

Intensive cognitive-behavioural therapy for recent onset schizophrenia: a pilot study
pp. 223-223(1)
Authors: Haddock G.; Hopkins R.; Tarrier N.; Morrison T.; Lewis S.

Successful transition from the hospital to the community
pp. 224-224(1)
Authors: Kopelowicz A.; Zarate R.; Wallace C.J.

Psychosocial rehabilitation in first-episode psychosis (FEP): experience with an FEP group
pp. 224-225(2)
Authors: Lazier L.; LeBlanc A.; Whitehorn D.; Kopala L.

Untreated psychosis and early intervention in recent onset schizophrenia
pp. 225-225(1)
Authors: Linszen D.H.; Lenior M.E.; Dingemans P.M.

Extroversion and work performance in schizophrenia
pp. 225-225(1)
Authors: Lysaker P.; Bell M.; Bryson G.

A group program for recovery from early psychosis
pp. 225-226(2)
Authors: Albiston D.J.; Francey S.M.; Harrigan S.M.; McGorry P.D.

Cognitively-oriented psychotherapy for early psychosis (COPE): preliminary results
pp. 226-226(1)
Authors: McGorry P.D.; Jackson H.; Edwards J.; Hulbert C.; Henry L.; Francey S.; Maude D.; Cocks J.; Power P.; Harrigan S.; Dudgeon P.

Coping strategies in relatives of patients with schizophrenia
pp. 227-227(1)
Authors: Scazufca M.; Kuipers E.

Quality of life and its relationship to patterns of service use among individuals with schizophrenia
pp. 227-227(1)
Authors: Scott J.E.; Lehman A.F.; Dixon L.B.; Postrado L.; Lyles A.; Skinner A.; Fahey M.

Cost study of intensive psychiatric community care for patients with psychosis
pp. 228-228(1)
Authors: Semple W.E.; Steiner E.; McCormick R.; Vernon L.; Schulz S.C.; Goyer P.F.

Acquisition of treatment compliance skills during recovery from acute exacerbation in schizophrenia
pp. 228-228(1)
Authors: Smith T.E.; Hull J.W.; Romanelli S.J.; Hedayat-Harris A.; Corriss D.J.; Goodman M.S.; Anthony D.T.

Factors associated with social behavior deficits in recently discharged schizophrenic patients
pp. 228-228(1)
Authors: Smith T.E.; Hull J.W.; Hedayat-Harris A.; Romanelli S.J.; Weiss K.A.; Raymond S.C.

Early detection and intervention programs for psychosis: service module development
pp. 228-229(2)
Authors: Spencer E.A.; O'Donnell M.C.; Shaw J.; Stewart K.; Still M.; Catts S.V.

Do mentally ill patients perceive their family members' expressed emotion?
pp. 229-229(1)
Authors: Tompson M.C.; Goldstein M.J.; Weisman A.

Cognitive adaptation training: the use of compensatory strategies for inpatients and outpatients with schizophrenia
pp. 229-229(1)
Authors: Velligan D.I.; Mahurin R.K.; Eckert S.L.; Miller A.L.; Bow-Thomas C.C.

First-episode schizophrenia: parent's role in determining the duration of untreated psychosis
pp. 230-230(1)
Authors: Whitehorn D.; Bayer M.J.; Kopala L.

P50 auditory gating, ffts, and plasma metabolites in schizophrenia
pp. 231-231(1)
Authors: Adler L.E.; McRae K.A.; Cawthra E.; Ascarrunz F.; Gerhardt G.; Huettl P.; Levin D.; Abrams R.; Freedman R.

Schizophrenic patients with normal prepulse inhibition?
pp. 231-231(1)
Authors: Perry W.; Geyer M.; Cadenhead K.; Swerdlow N.; Braff D.

Brain event-related potentials in schizophrenia during a visuospatial task
pp. 231-232(2)
Authors: Bruder G.; Kayser J.; Tenke C.; Friedman M.; Rabinowicz E.; Amador X.; Gorman J.

P50 suppression deficits among the relatives of schizophrenia patients
pp. 232-232(1)
Authors: Clementz B.A.; Geyer M.A.; Braff D.L.

Effects of haloperidol on the event-related potential in schizophrenics
pp. 232-232(1)
Authors: Condray R.; Steinhauer S.R.; Cohen J.D.; van Kammen D.P.; Kasparek A.; Kelley M.E.

Electrophysiology of differential cognitive load: an EEG study examining the frontal cortex
pp. 232-233(2)
Authors: Fleming K.; Mosko O.A.; Vovan B.; Chen E.; Yi J.; Potkin S.G.

Automatic but not strategic processing is abnormal in schizophrenics
pp. 233-233(1)
Authors: Ford J.M.; Roth W.T.; Bell C.M.; Yafeng L.; Jain S.; Menon V.; Lim K.O.; Pfefferbaum A.

P50 and experience of hypersensitivity to external stimuli
pp. 233-233(1)
Authors: Yi J.; Bunney W.E.; Hetrick W.P.; Sandman C.; Pateron J.; Potkin S.G.

Single dose challenge predicts clinical response to clozapine: a pharmaco-EEG study
pp. 233-233(1)
Authors: Yi J.; Potkin S.G.; Sandman C.; Bunney W.E.

Sensory gating deficit in schizophrenia: relation to cathecholamine metabolites
pp. 234-234(1)
Authors: Kang D.-Y.; Poole J.; McCallin K.; Fein G.; Vinogradov S.

Dissociation of ERP topographies for verbal and nonverbal auditory oddball tasks: findings for schizophrenic patients and healthy controls
pp. 234-234(1)
Authors: Kayser J.; Bruder G.; Tenke C.; Watson J.; Malaspina D.; Amador X.; Gorman J.

Automated analysis of EEG sleep deficits in schizophrenia
pp. 234-235(2)
Authors: Keshavan M.S.; Montrose D.; Miewald J.; Reynolds C.F.

Improved P50 auditory gating in schizophrenia with clozapine
pp. 235-235(1)
Authors: Nagamoto H.T.; Adler L.E.; Huettl P.; Gerhardt G.; Hea R.; Cawthra E.; Griffith J.; Freedman R.

Event-related potential and cognitive evidence for similar language impairments in schizophrenia and schizotypal personality disorder
pp. 235-236(2)
Authors: Niznikiewicz M.; Voglmaier M.; Seidman L.; Shenton M.; Dickey C.; Rhoads R.; Teh E.; McCarley R.W.

EEG coherence and symptom dimensions in schizophrenia
pp. 236-236(1)
Authors: Norman R.M.G.; Malla A.K.; Williamson P.C.; Morrison-Stewart S.; Helmes E.

Temporal P300 asymmetry in first episode schizophrenia
pp. 237-237(1)
Authors: Salisbury D.F.; Sherwood A.R.; Shenton M.E.; Fischer I.A.; Yurgelun-Todd D.A.; Tohen M.; McCarley R.W.

Temporal P300 asymmetry in schizophrenia vs. manic psychosis and controls
pp. 237-237(1)
Authors: Salisbury D.F.; Fischer I.A.; Shenton M.E.; Sherwood A.R.; Mazzoni P.; McCarley R.W.

Encoding vs trace decay: specifying the mechanism underlying auditory working memory dysfunction in schizophrenia
pp. 238-238(1)
Authors: Shelley A.-M.; Javitt D.C.; Vaughan H.G.; Silipo G.

P50 in deficit and nondeficit schizophrenia
pp. 238-238(1)
Authors: Summerfelt A.T.; Kohl K.; Kirkpatrick B.; Buchanan R.W.

Olfactory dysfunction in schizophrenia: relationship to ERP abnormalities
pp. 238-238(1)
Authors: Turetsky B.I.; Moberg P.J.; Doty R.L.; Gur R.C.; Gur R.E.

Auditory event-related potentials (ERP) in first episode and chronic schizophrenia
pp. 238-239(2)
Authors: Umbricht D.; Javitt D.; Bates J.; Pollak S.; Lieberman J.; Kane J.

Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia
pp. 239-239(1)
Authors: Umbricht D.; Javitt D.; Bates J.; Pollak S.; Lieberman J.; Kane J.

Sensory gating and clinical symptoms in schizophrenia: gender differences
pp. 239-239(1)
Authors: Vinogradov S.; Gourlay M.; Poole J.H.; McCallin K.; Fein G.

N400, indirect semantic priming and formal thought disorder
pp. 240-240(1)
Authors: Weisbrod M.; Kiefer M.; Brunnmaier A.; Spitzer M.

Motion perception deficits in schizophrenic patients and their correlation with abnormal smooth pursuit
pp. 241-241(1)
Authors: Yue C.; Nakayama K.; Holzman P.S.; Levy D.L.; Matthysse S.

Correlates of nailfold plexus visibility in first-episode and chronic schizophrenia
pp. 241-241(1)
Authors: Curtis C.E.; Iacono W.G.; Beiser M.

Eyelid conditioning--a non motivation-dependent tool to investigate temporal lobe function in schizophrenia
pp. 241-242(2)
Authors: Dantendorfer K.; Maierhofer D.; Serim M.; Eberstaller M.

Dynamic eye movements in schizophrenia, affective and schizoaffective disorders--a laboratory investigation using electrooculography
pp. 242-242(1)
Authors: Gerdsen I.; Pinkert J.; Foetzsch R.; Ripke B.; Oeser S.; Oehme L.; Bach O.; Franke W.G.

Ocular motor performance in schizophrenic patients and neurological patients
pp. 242-243(2)
Authors: Gooding D.C.; Iacono W.G.; Grove W.M.

Smooth pursuit abnormalities in first episode schizophrenic patients
pp. 243-243(1)
Authors: Hutton S.B.; Crawford T.J.; Puri B.K.; Duncan L.-J.; Kennard C.; Barnes T.R.E.; Joyce E.M.

Attentional measures and eye tracking in the finnish adoptive study of schizophrenia
pp. 243-244(2)
Authors: Moring J.; Wynne L.C.; Asarnow R.; Nuechterlein K.; Holzman P.S.; Hakko H.; Tienari P.

Eye-movement, attentional and frontal dysfunctions in schizophrenia
pp. 244-244(1)
Authors: Obuchowski M.; Cornblatt B.; Tak C.C.; Sweeney J.A.

Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome
pp. 244-244(1)
Authors: Ross D.E.; Thaker G.K.; Buchanan R.W.; Kirkpatrick B.; Lahti A.C.; Medoff D.R.; Bartko J.J.; Goodman J.; Tien A.Y.

Smooth pursuit eye movements in parents of schizophrenic probands; a most likely carrier approach
pp. 244-245(2)
Authors: Ross R.G.; Harris J.; Olincy A.; Radant A.; Adler L.; Freedman R.

Psychostimulant-associated pupillometric detection of subjects endorsing cocaine-induced paranoia
pp. 245-245(1)
Authors: Rosse R.B.; Johri S.K.; Alim T.N.; Ottaviani R.; Deutsch S.I.

Smooth pursuit eye movements (SPEM) to extraretinal motion signals in schizophrenia
pp. 245-245(1)
Authors: Thaker G.K.; Ross D.; Adami H.; Buchanan R.; Lahti A.

Effects of ketamine on eye tracking in schizophrenia and controls
pp. 246-246(1)
Authors: Weiler M.A.; Thaker G.K.; Lahti A.C.; Ross D.E.; Tamminga C.A.

Prediction of violence in schizophrenic inpatients
pp. 247-247(1)
Authors: Arango C.; Gonzalez T.; Calcedo A.

Psychosis after prenatal exposure to rubella
pp. 247-247(1)
Authors: Brown A.S.; Susser E.; Cohen P.

Neurological soft signs in first episode schizophrenia/schizophreniform psychosis
pp. 247-247(1)
Authors: Browne S.; Gervin M.; Lane A.; Morris M.; Larkin C.; Waddington J.L.; O'Callaghan E.

School performance and later schizophrenia in a finnish birth cohort
pp. 247-248(2)
Authors: Cannon M.; Jones P.; Huttunen M.; Murray R.

A prospective cohort study of genetic and perinatal influences in schizophrenia
pp. 248-248(1)
Authors: Cannon T.D.; Hollister J.M.; Bearden C.E.; Hadley T.

Gender and age-at-onset in the functional psychoses
pp. 248-248(1)
Authors: Castle D.J.; Wessely S.; Murray R.M.

Schizophrenia with onset at the extremes of adult life
pp. 248-249(2)
Authors: Castle D.J.; Wessely S.; Howard R.; Murray R.M.

Intensive use of cocaine in patients with schizophrenia: demographic and other features
pp. 249-249(1)
Authors: Cho J.; Jaskiw G.E.; Strauss M.E.; Goyer P.; Konicki P.E.

High prevalence of helicobacter pylori in schizophrenic patients
pp. 249-249(1)
Authors: De Hert M.; De Wilde D.; Reemans J.; Hautekeete M.; Peuskens J.

Homicide in Barbados: a review
pp. 250-250(1)
Authors: Evans C.; Malesu R.R.

Individual patient data meta-analysis of the association between schizophrenia and abnormalities of pregnancy and labour
pp. 250-250(1)
Authors: Geddes J.R.; Verdoux H.; Takei N.; Lawrie S.M.; Murray R.M.

Obstetric complications in schizophrenia, affective disorder and normal controls
pp. 251-251(1)
Authors: Gunduz H.; Woerner M.G.; Alvir J.M.J.; Lieberman J.A.

The predictors of schizophrenia in the 1966 Northern Finland birth cohort study
pp. 251-252(2)
Authors: Isohanni M.; Rantakallio P.; Jones P.; Hakko H.; Isohanni I.; Moring J.; Myhrman A.; Makikyro T.; Rasanen P.; Rasanen S.; Tiihonen J.

Reproductive pathology in women with schizophrenia and bipolar affective disorder: an epidemiological and clinical study
pp. 252-252(1)
Authors: Jablensky A.; Yellachich L.-A.; Zubrick S.; Morgan V.; Bower C.; Nguyen H.; Fazio S.; Montgomery P.; Castle D.

Summer birth and behavioral features in psychotic and nonpsychotic groups
pp. 252-253(2)
Authors: Kirkpatrick B.; Ram R.; Amador X.F.; LaPorte D.; Buchanan R.W.; McGlashan T.; Tohen M.; Bromet E.

Course of violence in schizophrenia: relationship to psychotic symptoms, neurological impairment and situational factors
pp. 253-253(1)
Authors: Krakowski M.; Czobor P.; Vitrai J.; Papezova H.; Libiger J.; Kunz M.

Maternal pre-eclampsia and schizophrenia: a case-control study with contemporaneously recorded obstetric data
pp. 253-253(1)
Authors: Kunugi H.; Nanko S.; Takei N.; Murray R.M.; Hirose T.

A prospective study of stress and outcome among patients with schizophrenia and their family caregivers
pp. 253-254(2)
Authors: Lukens E.; Butler P.; Thorning H.; Schecter D.

Do adverse events in early life increase the risk of schizophrenia?
pp. 254-254(1)
Authors: Meehan K.; Takei N.; McKenzie K.; Cannon M.; Murray R.

Influenza epidemics and the incidence of CNS disorders in Western Australia 1950-1960
pp. 254-255(2)
Authors: Morgan V.; Castle D.; Page A.; Montgomery P.; Gurrin L.; Burton P.; Fazio S.; Jablensky A.

What can we learn from the epidemic of schizophrenia in African-Caribbeans in the UK?
pp. 255-255(1)
Authors: Murray R.M.; Hutchinson G.; McKenzie K.; van Os J.

A prospective study of substance use disorders in a sample of patients with schizophrenia
pp. 255-255(1)
Authors: Newman R.M.; Nopoulos P.; Oliver S.; Andreasen N.C.

Infant feeding and the development of schizophrenia
pp. 255-256(2)
Authors: Peet M.; Poole J.; Laugharne J.

Comorbid substance misuse among people with schizophrenia in the community: an epidemiological study in central London
pp. 256-256(1)
Authors: McPhillips M.A.; Duke P.; Pantelis C.; Barnes T.R.E.

Suicidal behavior before the first hospitalization in psychotic disorders
pp. 256-256(1)
Authors: Radomsky E.D.; Haas G.L.; Keshavan M.S.; Sweeney J.A.

Schizophrenia, alcohol abuse and violent behaviour - A 26-year follow-up study of an unselected birth cohort
pp. 256-256(1)
Authors: Rasanen P.; Tiihonen J.; Isohanni M.; Rantakallio P.; Lehtonen J.; Moring J.

Nicotine dependence among schizophrenic inpatients
pp. 257-257(1)
Authors: Rogers T.; de Leon J.

Very poor outcome schizophrenia: a pilot study
pp. 257-257(1)
Authors: Roy M.-A.; Maziade M.

Seasonality of birth in schizophrenia and major affective illness in the Netherlands
pp. 257-258(2)
Authors: Selten J.P.; Dijkgraaf M.; van der Graaf Y.; Kahn R.S.

Second-trimester exposure to maternal stress is a possible risk factor for psychotic illness in the child
pp. 258-258(1)
Authors: Selten J.P.; van Duursen R.; van der Graaf Y.; Gispen-de Wied C.; Kahn R.S.

Stakeholder preferences for schizophrenia outcomes: an evaluation of assessment methods
pp. 258-258(1)
Authors: Shumway M.; Chouljian T.; Battle C.

Seasonal admission patterns in first episode schizophrenia
pp. 258-258(1)
Authors: Strous R.D.; Rokhsar M.; Robinson D.; Woerner M.G.

Medicare hospital utilization increasing for schizophrenia
pp. 259-259(1)
Authors: Swales T.P.; Sivinski L.D.; Karafa M.T.; Friedman L.; Schulz S.C.; Rimm A.A.

Six year mortality rates following hospitalization for schizophrenia
pp. 259-259(1)
Authors: Swales T.P.; Sivinski L.D.; Karafa M.T.; Friedman L.; Schulz S.C.; Rimm A.A.

18 year follow up of psychosis in afro-caribbean and white patients: a population-based study
pp. 259-259(1)
Authors: Takei N.; Persaud R.; Woodruff P.; Brockington I.; Murray R.M.

Age of onset distribution in schizophrenia for men and women: normal mixture density analysis
pp. 259-260(2)
Authors: Takei N.; Abel K.; Everitt B.; Jones P.; Murray R.M.

Seasonality of births in schizophrenia and bipolar disorder: a review of the literature
pp. 260-260(1)
Authors: Torrey E.F.; Miller J.; Rawlings R.; Yolken R.H.

City birth and schizophrenia incidence: is the relationship diagnosis-specific?
pp. 260-260(1)
Authors: van Os J.; Linnartz C.; Marcelis M.; Navarro F.; Selten J.-P.; Murray R.

First episode schizophrenia and borna disease virus
pp. 261-261(1)
Authors: Waltrip R.W.; Lieberman J.; Robinson D.; Bilder R.M.; Alvir J.M.; King L.R.; Summerfelt A.; Rubin S.A.; Carbone K.M.

The relationship of extrapyramidal symptoms and schizophrenia psychopathology
pp. 263-263(1)
Authors: Abraham G.; Tracy J.I.; Stanilla J.K.; Verghese C.; Simpson G.M.; Josiassen R.C.

Subjective response to neuroleptics in schizophrenia
pp. 263-264(2)
Authors: Arango C.; Sanz M.; Garcia I.; Gonzalez M.

Effects of clozapine and risperidone on force control
pp. 264-264(1)
Authors: Brescan D.W.; Ramirez L.F.; Jaskiw G.E.; Konicki P.E.; Vrtunski P.B.

Electroencephalographic pattern, side-effect profile and clozapine plasma levels in patients receiving 900 mg of clozapine
pp. 264-264(1)
Authors: Buckley P.F.; Miller D.D.; Richman C.; Chapman P.; Negron A.; Friedman L.

Cholesterol elevations associated with clozapine therapy
pp. 264-264(1)
Authors: Erickson B.R.; Reeve A.; Walter E.A.; Paine S.; Warner T.

Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to insight, subjective response to neuroleptics and attitudes to medication
pp. 264-265(2)
Authors: Garavan J.; Browne S.; Gervin M.; Lane A.; Kinsella A.; Larkin C.; O'Callaghan E.

Prevalence of extrapyramidal symptoms in patients treated concurrently with lithium and seroquel
pp. 265-265(1)
Authors: Kalali A.H.; Franklin D.; Carreon D.; Potkin S.G.

Prevalence of persistent clozapine induced sedation (CIS) and the effect on treatment
pp. 265-265(1)
Authors: Lauriello J.; Laframboise D.; Paine S.

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics
pp. 265-266(2)
Authors: Miller C.H.; Mohr F.; Umbricht D.; Woerner M.; Fleischhacker W.W.; Lieberman J.

Supersensitivity psychosis following clozapine discontinuation: myth or reality
pp. 266-266(1)
Authors: Potkin S.G.; Oldroyd J.; Jin Y.; Gulasekaram B.; Costa J.; Telford J.

Effects of low versus high potency neuroleptic withdrawal on symptoms and dyskinetic movements
pp. 266-266(1)
Authors: Schultz S.K.; Miller D.D.; Arndt S.; Andreasen N.C.

Chronic neuroleptic drug treatment induces mild gliosis in the prefrontal cortex of rhesus monkeys
pp. 266-267(2)
Authors: Selemon L.D.; Lidow M.S.; Goldman-Rakic P.S.

Clozapine effects on body weight, glucose and cholesterol levels
pp. 267-267(1)
Authors: Steele V.; Vokas C.S.; Jaskiw G.E.; Kwon K.Y.; Jurjus G.; White J.; Boyle D.; Konicki P.E.

Incidence of risperidone induced incontinence
pp. 267-267(1)
Authors: Vokas C.S.; Steele V.M.; Norris J.I.; Vernon L.T.; Brescan D.W.

Antipsychotic medication and specificity of behavioral effects: the force control approach
pp. 267-267(1)
Authors: Vrtunski P.B.; Jaskiw G.E.; Konicki P.E.

Clozapine vs. haloperidol: drug intolerance in a controlled six month trial
pp. 268-268(1)
Authors: Wirshing W.C.; Baker R.; Umbricht D.; Ames D.; Schooler N.; Kane J.; Marder S.R.; Borenstein D.

Spontaneous dyskinesia in first-episode schizophrenia
pp. 269-269(1)
Authors: Barnes T.R.E.; Puri B.K.; Chapman M.J.; Hutton S.B.; Joyce E.

Spontaneous dyskinesia in schizophrenia spectrum personality
pp. 269-269(1)
Authors: Cassady S.L.; Adami H.; Moran M.; Kunkel R.; Thaker G.

Spontaneous dyskinesia in first episode schizophrenia/schizophreniform psychosis
pp. 270-270(1)
Authors: Gervin M.; Browne S.; Lane A.; Clarke M.; Waddington J.L.; Larkin C.; O'Callaghan E.

Neurodevelopmental risk for tardive dyskinesia
pp. 270-271(2)
Authors: Goldman R.S.; Pappadopulos E.; Alvir J.M.A.; Reiter G.; Lieberman J.; Bilder R.M.

Clozapine in tardive dyskinesia
pp. 271-271(1)
Authors: Jurjus G.J.; Konicki E.P.; Popli A.P.; Kwon K.Y.

The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients
pp. 271-271(1)
Authors: McCarthy M.F.; Kendrick K.A.; Rosse R.B.; Schwartz B.L.; Peace T.; Wyatt R.J.; Deutsch S.I.

Tardive dyskinesia and extrapyramidal symptoms in treatment-resistant schizophrenics treated with clozapine
pp. 272-272(1)
Authors: Nair C.; Abraham G.; Stanilla J.K.; Simpson G.M.; Josiassen R.C.

Negative symptom and neuropsychological precursors of tardive dyskinesia
pp. 272-272(1)
Authors: Quinlan D.M.; McGlashan T.H.; Schuldberg D.; Glazer W.

TD symptom decreases with regulation of plasma large neutral amino acids
pp. 272-272(1)
Authors: Richardson M.A.; Bevans M.L.; Weber J.B.; Gonzalez J.J.; Flynn C.J.; Amira L.; Suckow R.F.; Maher T.J.

Neurochemical actions of typical and atypical neuroleptics in basal ganglia and thalamus
pp. 273-273(1)
Authors: Sakai K.; Xue-Min G.; Tamminga C.A.

Tardive dyskinesia scores as predictor of relapse with neuroleptic dose reduction
pp. 273-273(1)
Authors: Strous R.D.; Faraone S.V.; Richards C.; Yin P.; Gutierrez J.; Tsuang M.T.; Green A.I.

Insight and anosognosia of tardive dyskinesia in schizophrenia
pp. 273-273(1)
Authors: Tremeau F.; Amador X.; Malaspina D.; Amodt I.; Goetz R.; Gorman J.M.

< previous issue | all issues | next issue >

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page